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CDC45 Function Alters Cell Sensitivity to DNA Topoisomerase I Poisons
Abstract
Eukaryotic DNA topoisomerase I (Top1) is a highly conserved enzyme that functions to manage the
torsional strain of DNA during cellular processes such as transcription, replication, chromatid
condensation and recombination. The enzyme binds duplex DNA and through a series of strand cleavage
and religation reactions removes positive or negative supercoils relieving torsional strain. Top1 is the sole
cellular target of the anticancer agent camptothecin, which stabilizes the covalent complex. CPT
cytotoxicity is S-phase dependent. It has been suggested that the mechanism of this S-phase toxicity is
due to the advancing replication forks either colliding with the stabilized drug-enzyme-DNA intermediate
or colliding with positive supercoils that accumulate in front of the advancing forks leading to S-phase
dependent lesions, inhibition of DNA replication and cell death. Despite extensive study, the exact events
leading to cell death or repair of these lesions have yet to be defined.
Using the genetically tractable budding yeast, S. cerevisiae, as a model system, a genetic screen was
designed to isolate conditional temperature sensitive mutants that exhibit enhanced sensitivity to the CPT
mimetic, Top1T722A. This genetic screen identified several recessive mutants (tah mutants) involved in a
variety of cellular pathways including CDC45, DPB11, TAH11, which encode essential products for DNA
replication and UBC9, which encodes an E3 SUMO ligase.
The tah mutant cdc45-10 has a single amino acid substitution (G510R). These cells are hypersensitive to
Top1T722A and transiently accumulate in early S-phase when shifted 36˚C due to a defect in Okazaki
fragment maturation. These cells also exhibit a slow growth phenotype when a component of the DNA
damage checkpoint, RAD9, is deleted and is synthetically lethal with another tah mutant dpb11-10 at 36˚C
suggesting that cdc45-10 exhibits defects in DNA replication. To understand how Cdc45 functions to
protect cells against Top1-induced DNA damage, the defects in cdc45-10 were characterized.
We identified cdc45-10 as a hypomorphic allele and increased gene dosage of this mutant allele restored
cell viability in the presence of Top1T722A at 36˚C, however, increased gene dosage failed to restore cell
viability to the cdc45-10,dpb11-10 double mutant strain suggesting that the defects in cdc45-10that
specific to Top1T722A sensitivity are distinct from the defects in the synthetic interaction of cdc45-10 and
dpb11-10. These two distinct functions of Cdc45 were supported by results obtained from further
characterizing the defects in cdc45-10 using a dosage suppressor screen to identify extragenic
suppressors that complement cdc45-10 cell sensitivity to Top1T722A and our attempts to epitope tag
Cdc45 and cdc45-10.
The cdc45-10 defects in origin firing and replication fork progression were characterized by isolating
replication intermediates and resolving them using 2-D gel electrophoresis.
Several lines of evidence including our report that cdc45-10 is hypersensitive to the antibiotic rapamycin
(RAP), suggests a role for TOR signaling in S-phase. To investigate this possibility we isolated replication
intermediates that were treated with MMS, RAP, HU or combinations of these drugs and origin firing and
replication fork progression was visualized using 2-D gel electrophoresis.
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ABSTRACT

Eukaryotic DNA topoisomerase I (Top1) is a highly conserved enzyme that
functions to manage the torsional strain of DNA during cellular processes such as
transcription, replication, chromatid condensation and recombination. The enzyme binds
duplex DNA and through a series of strand cleavage and religation reactions removes
positive or negative supercoils relieving torsional strain. Top1 is the sole cellular target of
the anticancer agent camptothecin, which stabilizes the covalent complex. CPT
cytotoxicity is S-phase dependent. It has been suggested that the mechanism of this Sphase toxicity is due to the advancing replication forks either colliding with the stabilized
drug-enzyme-DNA intermediate or colliding with positive supercoils that accumulate in
front of the advancing forks leading to S-phase dependent lesions, inhibition of DNA
replication and cell death. Despite extensive study, the exact events leading to cell death
or repair of these lesions have yet to be defined.
Using the genetically tractable budding yeast, S. cerevisiae, as a model system, a
genetic screen was designed to isolate conditional temperature sensitive mutants that
exhibit enhanced sensitivity to the CPT mimetic, Top1T722A. This genetic screen
identified several recessive mutants (tah mutants) involved in a variety of cellular
pathways including CDC45, DPB11, TAH11, which encode essential products for DNA
replication and UBC9, which encodes an E3 SUMO ligase.
The tah mutant cdc45-10 has a single amino acid substitution (G510R). These cells
are hypersensitive to Top1T722A and transiently accumulate in early S-phase when
shifted 36˚C due to a defect in Okazaki fragment maturation. These cells also exhibit a
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slow growth phenotype when a component of the DNA damage checkpoint, RAD9, is
deleted and is synthetically lethal with another tah mutant dpb11-10 at 36˚C suggesting
that cdc45-10 exhibits defects in DNA replication. To understand how Cdc45 functions
to protect cells against Top1-induced DNA damage, the defects in cdc45-10 were
characterized.
We identified cdc45-10 as a hypomorphic allele and increased gene dosage of this
mutant allele restored cell viability in the presence of Top1T722A at 36˚C, however,
increased gene dosage failed to restore cell viability to the cdc45-10,dpb11-10 double
mutant strain suggesting that the defects in cdc45-10 that specific to Top1T722A
sensitivity are distinct from the defects in the synthetic interaction of cdc45-10 and
dpb11-10. These two distinct functions of Cdc45 were supported by results obtained from
further characterizing the defects in cdc45-10 using a dosage suppressor screen to
identify extragenic suppressors that complement cdc45-10 cell sensitivity to Top1T722A
and our attempts to epitope tag Cdc45 and cdc45-10.
The cdc45-10 defects in origin firing and replication fork progression were
characterized by isolating replication intermediates and resolveing them using 2-D gel
electrophoresis.
Severeal lines of evidence including our report that cdc45-10 is hypersensitive to
the antibiotic rapamycin (RAP), suggests a role for TOR signaling in S-phase. To
investigate this possibility we isolated replication intermediates that were treated with
MMS, RAP, HU or combinations of these drugs and origin firing and replication fork
progression was visualized using 2-D gel electrophoresis.
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CHAPTER 1: INRODUCTION

1.1 EUKARYOTIC DNA TOPOISOMERASES
DNA topoisomerases are responsible for managing the topological state of DNA
in a cell. Due to the double helical nature of DNA, topoisomerases are needed for
processes such as transcription and recombination, in which two strands of the helix must
separate temporarily, or replication, in which the two strands separate permanently (1,2).
There are two subfamilies of DNA topoisomerases: type I enzymes cleave a
single strand of DNA, while type II enzymes cleave both strands of the DNA duplex to
generate a double-strand break (1,2). Type I enzymes are further divided into IA and IB,
where IA enzymes link the protein to a 5’ phosphate and relax negatively supercoiled
DNA, while IB enzymes link the protein to a 3’ phosphate and relax both positively and
negatively supercoiled DNA (1,2). Type IA enzymes promote passage of the intact
strand through the broken strand, while type IB enzymes leave the broken strand free to
rotate around the intact strand (3). Type II enzymes are also organized into two families,
Top IIA and Top IIB. All type II enzymes require ATP binding and hydrolysis to
facilitate catenation or decatenation of duplex DNA. Top II enzymes are essential in all
cells for segregation of chromosomal DNA after DNA replication and before cell division
(3).
DNA topoisomerase I (Top1), a type IB enzyme, is highly conserved from yeast
to human in sequence and domain structure, reaction mechanism and camptothecin
sensitivity. In higher eukaryotes, Top1 is essential as TOP1 knockout mice die early
during embryogenesis (4). In the budding yeast Saccharomyces cerevisiae TOP1 is
1

nonessential, although top1 null mutants show a slight growth defect at lower
temperatures and increased recombination at rDNA loci (5). As diagrammed in Fig. 1.1,
Top1 contains four domains: an unstructured, poorly conserved, nonessential N-terminal
domain, a highly conserved core domain that binds DNA, a poorly conserved linker
domain and a conserved C-terminal domain that contains the active site tyrosine (1). As
shown in Fig. 1.2, Top1 is a monomeric enzyme that forms a protein clamp around
duplex DNA. The enzyme transiently cleaves a single DNA strand when a
phosphodiester bond in the DNA undergoes nucleophilic attack by the active site tyrosine
to generate a phosphotyrosyl linkage between the enzyme and the 3’ phosphate of the
nicked DNA. The noncovalently bound end of DNA is free to rotate around the
covalently held strand relieving torsional strain and changing the linking number of
DNA. In a second transesterification reaction, the nick is religated and the covalent
enzyme-DNA complex is resolved (5).
Studies in yeast and mammalian cells have identified Top1 as the sole cellular
target of the anticancer drug camptothecin (CPT). Early studies using yeast strains
deleted for TOP1 showed cells were resistant to CPT while the introduction of a plasmid
expressing human or yeast TOP1 into these cells restored CPT sensitivity (6).
Camptothecin was isolated from the bark of the Chinese tree, Camptotheca acuminata
(4). Animal studies showed that camptothecin exhibited potent antitumor activity against
a broad spectrum of tumors, however, in the early 1970s clinical trials were discontinued
due to toxicity (4,7). CPT reversibly stabilizes the covalent Top1-DNA intermediate and
inhibits the religation step of the catalytic cycle. Stabilized covalent intermediates can be
formed in every stage of the cell cycle. Analysis of replication intermediates using the
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Fig. 1.1 DNA topoisomerase I
DNA Top1 is highly conserved from yeast to human. It has a nonessential N-terminal
domain, a core domain that forms a protein clamp around duplex DNA, a poorly
conserved linker domain and a conserved C-terminal domain that contains the active site
tyrosine (Tyr727 in yeast and Tyr723 in mammalian cells).
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Fig. 1.2 Catalytic cycle of eukaryotic DNA topoisomerase I
DNA Top1 is a monomeric enzyme that forms a protein clamp around duplex DNA, first
noncovalently, then covalently by nicking a single strand of the DNA and forming a
phosphotyrosyl linkage with the 5’end leaving the 3’ end free to rotate around the
covalently held strand unwinding the DNA. After rotation, the nick is religated and the
enzyme and DNA dissociate. The anti-tumor drug CPT stabilizes these covalent
complexes and advancing replication forks collide with these drug-enzyme-DNA
complexes resulting in irreversible DNA lesions that cause S/G2 arrest, inhibition of
replication and cell death. Mutations in the Top1 protein change the catalytic activity of
the enzyme. Substituting Asn 726 for His results in a Top1 enzyme that exhibits an
increase in the rate of DNA cleavage without changing the rate of religation. Mutating
Thr 722 to Ala results in an enzyme that is defective in religating the cleaved DNA
strand, mimicing the cytotoxic action of CPT.
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SV40 cell-free replication system showed that collision of the replication fork and TOP1
cleavable complexes leads to three distinct events: the formation of a double strand break
at the fork, irreversible arrest of replication fork movement and formation of an
irreversible TOP1-DNA covalent adduct leading to S-phase specific cell death and arrest
in G2 phase of the cell cycle (7).
More recent single molecule studies of human Top1 suggest an alternative
mechanism for CPT induced cell death whereby drug binding of the CPT analog
topotecan to Top1-DNA complexes induces accumulation of positive supercoils in front
of moving replication forks. These local domains of high superhelical density would
block fork progression, resulting in fork collapse and lethal DNA lesions that induce cell
death (8).
Since Top1 was identified as the cellular target of CPT, several water-soluble
derivatives have been developed including topotecan and the prodrug irinotecan. There
are several properties that make the camptothecins unique. First, identification of Top1 as
the cellular target in yeast and mammalian cells: yeast cells deleted for Top1 are resistant
to CPT and in vertebrate cell lines, single point mutations exist that render Top1 resistant
to CPT. Second, within minutes of exposure, CPT can penetrate vertebrate cells, target
Top1 and reversibly bind to Top1 cleavable complexes. Third, micromolar drug
concentrations of CPT and its derivatives are needed to detect trapped Top1 cleavable
complexes in biochemical assays suggesting camptothecins have a low affinity for Top1
cleavable complexes (4).
The amino acids located immediately N-terminal to the active site tyrosine are
highly conserved between yeast and human enzymes. Several amino acid substitutions of
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these residues have been reported to affect CPT sensitivity and enzyme catalysis (5). For
example, in yeast or human Top1, substituting the two residues preceding the active site
Tyr to Arg and Ala rendered the enzymes resistant to CPT. Biochemical studies indicated
no difference in enzyme specific activity, however, in DNA cleavage assays the mutant
enzymes exhibited diminished levels of CPT stabilized covalent complexes. These results
suggest the levels of drug-stabilized enzyme-DNA complexes correspond with the
cytotoxic activity of CPT in cells expressing the mutant enzymes (5).
Substituting Ala for Thr 722 in yeast or the corresponding residue in human Top1
creates an enzyme that mimics the action of CPT by increasing the stability of the
covalent enzyme-DNA intermediate. The mutant enzyme was catalytically active, yet
exhibited a defect in DNA religation, yielding higher concentrations of covalent
intermediates (5).
Mutating the Asn immediately preceding the active site Tyr to different amino
acids effects various aspects of Top1 function. Substituting Asn with Leu or Asp reduces
the specific activity of the enzyme and reduces enzyme sensitivity to CPT. In contrast,
mutating Asn to Ser or His had little effect on the specific activity of the enzyme.
However, the Ser mutation rendered the enzyme resistant to CPT while the His mutation
enhanced enzyme sensitivity to CPT and increased the rate of DNA cleavage (5).
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1.2 EUKAYROTIC DNA REPLICATION

1.2.1 Origins and ORC
Eukaryotic cell division is a multi-step process where cells must faithfully
replicate the entire nuclear content of DNA once and only once per cell cycle to maintain
genomic integrity and chromosome ploidy (9). Timely duplication of DNA is
accomplished when cells initiate replication from hundreds or even thousands of origins.
The genetically tractable yeast system has been central in understanding the temporal
order of events that must occur for cells to faithfully replicate DNA. In yeast initiation
occurs at Autonomously Replicating Sequences (ARS) sequences that are distributed
widely throughout the genome and fire in a temporally regulated pattern (10). Origin
structure varies from species to species. S. cerevisiae origins are defined blocks of
sequences approximately 100-200 base pairs in length (11). ARS elements are A/T rich
regions that contain an 11bp consensus sequence (5’-(A/T)TTTAT(A/G)TTT(A/T)-3’)
(9). This ARS consensus sequence (ACS) and immediate flanking sequences are called
domain A. This domain is essential as deletion or mutation completely abolishes ARS
function and is a unique identifier of replication origins (11). However, domain A itself is
not sufficient for ARS activity. Sequences flanking domain A, domain B and C,
contribute to ARS function. Domain B consists of sequences 3’ to the T-rich strand of the
ACS and enhances the efficiency of origin utilization while domain C consists of
sequences 5’ to the T-rich strand (9).
Variations in efficiency and timing exist among origins. The temporal pattern of
origin firing is such that origins are licensed to fire in late G1-phase. However DNA
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synthesis is not initiated until S-phase when additional proteins are recruited to the
origins as a consequence of Dbf4-dependent kinase and the cyclin-dependent kinase
activity (discussed in detail below). These two kinases act on converging pathways to
allow fail-safe activation of origins in S-phase and simultaneously prevent re-licensing of
an origin (10). Strong or efficient origins fire in most S-phases while weak or inefficient
origins fire only if replication is delayed. Early origins fire at the onset of S-phase while
late firing origins are activated by Clb5/Cdk in late S-phase to complete DNA synthesis
(10). Cryptic origins are those that only fire in S-phase when replication has been
interrupted. For example, the cryptic origin, ARS301, fires in Rad53 defective strains
exposed to DNA damaging agents (12)
The six-subunit origin recognition complex (Orc), consisting of Orc1-6, was one
of the first origin binding protein complexes identified and remains bound to the origin
throughout the cell cycle. Orc is highly conserved in eukaryotes and archaea and is a
sequence specific binding protein complex that recognizes the core sequence of the
origin. Orc binds to active replication origins as well as transcriptional silencers,
telomeric DNA and cryptic origins, suggesting that it may act as a landing platform for
other chromosomal proteins (10).

1.2.2 Pre-replicative complex formation
To ensure that each origin fires once and only once during each S-phase, origin
function is regulated in two discreet steps: pre-replicative complex (pre-RC) formation in
G1-phase of the cell cycle and initiation of DNA replication in S-phase, as shown in Fig.
1.3. In G1-phase, pre-RC formation involves the sequential binding of Cdc6, Tah11
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Fig. 1.3 DNA replication
At the end of mitosis a decrease in Cdk-Clb kinase activity allows pre-replicative
complex formation consisting of Orc, Mcm2-7, Tah11 and Cdc6. Cells pass through
“START” in G1-phase committing them to DNA replication. As cells begin to transit
from late G1 to S-phase, Dbf4-Cdc7 and Clb5/6-Cdc28 protein kinases become active
and phosphorylate components of the pre-RC promoting the recruitment of Cdc45 and
GINS. Once DNA replication is initiated, Dpb11 recruits Pol ε and facilitates the switch
between Pol α and Pol ε. Mcm2-7, GINS and Cdc45 move with replication forks as
elongation occurs.

9

(Cdt1), and the Mcm2-7 complex to the Orc bound origin (13). Cdc6 and Tah11 first bind
to Orc, Orc and Cdc6 then hydrolyze ATP to promote loading of Mcm2-7 on the DNA.
The contribution of Tah11 in this process remains unclear. Cdc6 is phosphorylated upon
origin activation by the cyclin dependent kinases (CDK), Dbf4-Cdc7 and Clb5/6-Cdc28,
leading to protein degradation or nuclear export restricting its activity to the G1/S-phase
of the cell cycle. Cdt1 (Tah11) is regulated in metazoans when geminin binds Cdt1 and
prevents its activity in G2-phase or mitosis (10). The Mcm2-7 complex has a hexameric
ring structure that is highly suggestive of a replicative DNA helicase. In S. cerevisiae,
Mcms cycle in and out of the nucleus during the cell cycle. In other organisms they are
located in the nucleus throughout the cell cycle, but binding to chromatin only occurs
during G1/S-phase. In all eukaryotes, the Mcm2-7 complex is dislodged from the
chromatin to move with replication forks. Assembly of Orc, Cdc6, Tah11, and Mcm2-7
at the origin completes the pre-RC, effectively licensing the origin for DNA replication in
the subsequent S-phase (10).
For licensed origins to initiate DNA replication, however, they must pass through
the G1 decision point, called START, which irreversibly commits the cells to a new
round of cell division. START is properly executed when Cdc28, a cyclin dependent
kinase, becomes active by forming a complex with Cln1/2. Nine cyclins modulate Cdc28
activity: three G1 cyclins, Cln1-3, which are required for the passage through START
and six B-type cyclins, Clb1-6, which are involved in S-phase and mitotic progression.
The G1 cyclins are those that act on the pre-RC and lead directly to the initiation of DNA
replication (9). Early studies showed that any of the three Cln proteins could compensate
for the loss of another without affecting START. However, there are different functions
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of Cln1-3. Cln1 and Cln2 are highly similar proteins, whose expression is cell cycle
regulated with levels peaking in late G1. Cln3 is less similar to Cln1 and Cln2 and is
constitutively expressed throughout the cell cycle. Cln3 is responsible for activating the
transcription of select genes in late G1 phase, including CLN1 and CLN2. Induction of
these transcripts leads to an increase in Cln1/2-Cdc28 kinase activity, which catalyzes
most or all of the events associated with START (9).
Cln1/2-Cdc28 kinase activation is required for DNA replication to occur, however
it is the B-type cyclins, Clb5 and Clb6, which directly activate origin firing. Clb5/Clb6Cdc28 complexes are formed in late G1-phase, but are kept inactive by the CDK inhibitor
Sic1. Sic1 has two functions in the cell cycle. First, it contributes to the shut off of the
mitotic form of the Clb-Cdc28 kinase promoting the exit of a cell from mitosis. Second,
Sic1 regulates the activity of Clb5/6-Cdc28 kinase, thereby controlling the timing of Sphase. A primary function of Cln1/2-Cdc28 is to target Sic1 for degradation to promote
entry into S-phase. It was shown in wild-type cells that Sic1 accumulates in late mitosis,
is phosphorylated at START in a Cln-dependent manner and is degraded shortly before
S-phase. Sic1 degradation is dependent both on Cdc34, an ubiquitin-conjugating enzyme,
and on the Cln-Cdc28 kinase. Following the down regulation of Sic1, the Clb5/6-Cdc28
kinase is activated (9).
A second protein kinase, Dbf4-dependent kinase (DDK), is also required for Sphase entry. DDK consists of a catalytic subunit Cdc7 and a regulatory subunit Dbf4 that
confers substrate specificity (10). Cdc7 protein levels are constant throughout the cell
cycle. However, kinase activity is periodic, peaking at the G1/S boundary. Activation of
the Cdc7 kinase requires interaction with the regulatory subunit Dbf4, which is expressed
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in late G1-phase and turned over rapidly allowing for a short burst of Cdc7 activity at the
beginning of S-phase. Thus, Cdc7 kinase activity appears to be the last regulatory step
before the initiation of DNA replication (9).

1.2.3 Initiation of DNA replication
The initiation of replication, or origin firing, occurs as cells enter S-phase (13).
Activation of the pre-RC by protein kinases results in Cdc45 binding to the Mcm2-7
complex (14), which appears to be the most critical event in origin firing. Both Cdc45
and the Mcms are required for initiation and elongation steps of DNA replication. Cdc45
is less abundant than the Mcm proteins and is therefore rate limiting for replication. The
ratio of the Mcm2-7 complex to ORC is 40:1 while the ratio of Cdc45 to Orc is 2:1 (10).
Both Cdc7/Dbf4 and Clb-Cdc28 activity is required for Cdc45 loading. In addition, this
step may be mediated by Dpb11, which is part of a CDK-regulated complex and is
required for Cdc45 loading. One model suggests that DDK phosphorylation of Mcms
causes a change in the complex to allow a limited amount of Cdc45 to bind to the Mcms
at the origin (10). Once Cdc45 is bound, the replication origins unwind to allow binding
of the single strand DNA binding protein Rpa, then DNA polymerase alpha (α) and
epsilon (ε) are recruited (10,14). Origin unwinding depends on Cdc45 forming a complex
with Sld3. SLD3 was isolated in S. cerevisiae as a gene interacting with DPB11. Dpb11,
when bound by Sld2/Drc1 associates with DNA polymerase ε at the replication origin
(14). There are at least two independent functions of Dpb11. It is required for the
initiation of DNA replication and is important for checkpoint responses to unreplicated or
damaged DNA.
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There is some evidence that the Mcm2-7 complex has helicase activity and all six
Mcms are required for DNA unwinding. Moreover, Cdc45 may be the essential cofactor
that converts the Mcm complex to an active DNA helicase. The GINS complex also
appears to be essential for DNA unwinding. GINS is a ring-shaped, four protein complex
that is highly conserved from archaea to eukaryotes (10), which is required for the
loading of both Cdc45 and Dpb11 onto origin DNA and then becomes associated with
moving replication forks (15).
Another protein, Mcm10, also participates in recruiting Cdc45 to origin DNA and
regulates DNA polymerase α stability (10,16). After the replication origins have been
activated, the Mcm2-7 complex and Cdc45 move with the assembled replication enzymes
at the forks to complete DNA replication. After initiation, the movement of the Mcm2-7
complex away from the origin converts the origin to an unlicensed state thus preventing
re-initiation (14).
After DNA unwinding is initiated, the DNA synthesis machinery, the replisome,
is assembled and DNA replication begins. DNA synthesis begins with DNA polymerase
α associating with primase to initiate a short RNA primer, which is then extended by
DNA polymerases. Next, DNA polymerase α is replaced with the more processive
polymerases, delta (Δ) or epsilon (ε). At the same time, PCNA, the “sliding clamp”
processivity factor is loaded. PCNA loading is dependent on a clamp-loading complex
replication factor C (Rfc), which promotes the polymerase switch. One strand of DNA is
synthesized as the leading strand the other as the lagging strand. Leading strand synthesis
is very efficient, highly processive and follows closely behind the helicase. Lagging
strand synthesis requires multiple cycles of priming and extension as the underlying DNA
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is exposed and synthesis occurs in the direction away from the helicase. Lagging strand
synthesis results in Okazaki fragments that must be processed by nucleases and DNA
ligase to create a single DNA chain. To protect the underlying DNA and ensure
completion of DNA synthesis, leading and lagging strand synthesis remains coupled
throughout S-phase (10).

1.2.4 Cdc45
To better understand the process of cell division, a cold sensitive (cs) genetic
screen in S. cerevisiae was used to identify more than 40 essential genes whose products
were needed to carry out cell division. One mutant, cdc45-1 (for cell division cycle 45),
was shown to arrest at medial nuclear division, with a single large bud and the nucleus in
the neck between the mother and daughter (17).
Several groups simultaneously reported the isolation of a gene encoding the
Cdc45 protein. Zou and colleagues reported the predicted protein sequence of S.
cerevisiae Cdc45 as a 74.2 kilo Dalton (kDa) acidic protein with a bipartite nuclear
localization sequence. The cold sensitive mutant, cdc45-1, is defective in initiating DNA
replication and has inefficient origin firing at the non-permissive temperature suggesting
Cdc45 functions at replication origins and affects the frequency of origin firing. cdc45-1
is synthetically lethal with orc2-1, mcm2-1 and mcm3-1 confirming the interaction of
Cdc45 with Mcm and ORC and further suggesting that all three act together in the
initiation of DNA replication (18).
At the same time, Hopwood and Dalton reported the isolation of Cdc45 as a 650
amino acid polypeptide that is essential for the initiation of chromosomal DNA
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replication in S. cerevisiae, yet shows no obvious homology with the Mcm family of
proteins. They used a conditional cdc45 null mutant strain where the Cdc45 protein can
be rapidly degraded at 37° due to a signal peptide that was fused to the N-terminus
creating a temperature-sensitive degron signal. At 37°C this strain is not viable. The cells
arrest uniformly at the G1/S boundary with a 1N DNA content suggesting Cdc45 is
required for an early step in DNA replication. This phenotype is similar to the cold
sensitive cdc45-1 mutant that was previously characterized and the same as the
phenotype associated with many Mcm mutants. In immunoprecipitation studies,
Hopwood and Dalton showed that Cdc45 forms a complex with Mcm5 in the Mcm2-7
multi-protein complex and is localized in the nucleus throughout the cell cycle. In
contrast, the Mcm proteins shuttle in and out of the nucleus in a cell cycle dependent
manner. Hopwood and Dalton mapped the canonical bipartite nuclear localization signal
(NLS) to residues 209-228 as mutations of these residues abolish Cdc45 nuclear import
(19). A bipartite NLS consists of two essential interdependent domains of basic amino
acids separated by a 10 amino acid spacer (20).
By complementation of the cold sensitive cdc45-1 mutant, Hardy mapped CDC45
to an open reading frame on Chromosome XII. FASTA/BLAST analysis suggested
Cdc45 was similar toTsd2 from Ustilago maydis, which also has a role in DNA
replication (19,21). The amino acid sequences of Cdc45 and Tsd2 are 30% identical and
50% similar. Hardy also reported that CDC45 is G1/S cell cycle regulated at the mRNA
level. The MluI cell cycle box (MCB) is the upstream regulatory sequence that drives
G1/S specific gene expression and enzymes involved in DNA synthesis are
transcriptionally regulated by MCB elements in their upstream non-translated sequences.
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CDC45 contains two MluI sites 145 base pairs and 175 base pairs upstream of the start
codon. An analysis of CDC45 RNA levels showed transcription peaks in early G1 and is
diminished as cells enter S-phase suggesting regulation is in a G1/S specific manner. This
is consistent with the pattern of other MCB regulated genes such as PCNA (21).
However, the Cdc45 protein appears to be long-lived and is constant throughout the cell
cycle.
Another mutant allele of Cdc45 is cdc45-10. This temperature sensitive allele was
isolated in the Bjornsti lab using a S. cerevisiae genetic screen to identify conditional
mutants with enhanced sensitivity to DNA Top1-mediated DNA damage. Since yeast
sensitivity to CPT is modulated by the pleiotropic drug resistance network, the selfpoisoning Top1T722A mutant was used as a source of DNA damage (5). Substituting Ala
for Thr722 increases the stability of the covalent Top1-DNA intermediate, mimicing the
cytotoxic action of CPT. The cdc45-10 mutant encodes a Gly to Arg substitution at
amino acid 510 near the C-terminus of the protein (22). The mutant cells exhibit
enhanced sensitivity to CPT, UV and a replication inhibitor hydroxyurea (HU), at the
non-permissive temperature, 36°C (5). cdc45-10 cells also transiently accumulate in early
S-phase when shifted to 36°C due to defective Okazaki fragment maturation. These cells
exhibit a slow growth phenotype at 36° when a component of the DNA damage
checkpoint, Rad9, is deleted suggesting that the damage occurring in these cells is
recognized by this pathway (22).
As described above, Cdc45 is a member of a growing number of gene products
that are required for cells to initiate DNA replication. Cdc45 associates with chromatin at
the G1/S transition after “START” as cells move to S-phase and this is crucial for
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committing the cells to initiation of DNA replication (23,24). Cdc45 is also required for
Polα loading onto chromatin and associates with Mcm2, Rpa and Polε a part of the
elongation machinery. It is suggested that Cdc45 and Rpa may continually stimulate
Mcm helicase activity during replication elongation (25). Sld3 is another protein that is
required for Cdc45 binding at origins. Sld3 and Cdc45 must form a complex in order for
either protein to associate with origin DNA. Studies have shown that the Sld3-Cdc45
complex associates with origins through the interaction of Cdc45 and the Mcm2-7
complex. Once Sld3-Cdc45 is bound, origin DNA unwinds and is bound by replication
factor A (RF-A), the single-strand DNA binding protein (15). The function of Sld3 is
limited to events prior to initiation; it is not required for the completion of replication
once early origins have fired and does not move with replication forks. In contrast, the
GINS complex is not needed for the initial recruitment of Cdc45 but is required for the
stable engagement of Cdc45 with the previously bound replication machinery, and then
becomes stably associated with the Mcm2-7 complex during replication elongation (26).
Due to its ring-like shape, GINS may act as a clamp for replication proteins such as Pol ε
that function during the elongation steps of replication (15). In vitro GINS forms a 1:1
complex with Polε and greatly stimulates its catalytic activity. Polε is also more
processive and dissociates from replicated DNA more easily when GINS is present. The
GINS complex has also been show to promote the interaction between Sld2-Dpb11-and
Polε (27). Dpb11 is required for DNA polymerases to associate with origins. Sld2 and
Dpb11 form a complex when Sld2 is phosphorylated by S phase Cdk activity and this
complex is essential for DNA replication. Dpb11 is required for GINS association with
origin DNA. The interaction between GINS and Dpb11 must be limited to assembly at
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origin DNA because Dpb11 dissociates from replication forks after its function is
complete and therefore does not move with replication forks during elongation (15).
dpb11-10 is a temperature sensitive allele that was isolated from the same genetic screen
as cdc45-10. dpb11-10 cells exhibit a similar phenotype to cdc45-10 cells: they are
hypersensitive to CPT, UV and HU at 36°C and they transiently accumulate in early Sphase at 36°C due to a defect in Okazaki fragment maturation (22). A double mutant
strain, containing both the cdc45-10 and dpb11-10 mutations, is temperature sensitive for
growth at 36°C in the absence of DNA damage, indicating a synthetic interaction
between Cdc45 and Dpb11 (22).
CDC45L is the human homolog of S. cerevisiae CDC45. It is 30 kilobases long
with 15 introns and 16 exons that encode a protein of 566 amino acids with a molecular
mass of 64 kDa. Cdc45L is 27.6% identical and 52% similar to S. cerevisiae Cdc45 and
26.8% identical and 49.5% similar to Ustilago maydis Tsd2p. Like the fungal proteins,
Cdc45L also contains a bipartite nuclear localization signal. Cdc45L mRNA levels
increase during the G1/S transition, but protein levels remain constant throughout the cell
cycle, which is typical of proteins involved in the initiation of DNA replication. The
Cdc45L gene is located on chromosome 22q11.2 and one copy of the gene is frequently
deleted in DiGeorge syndrome (DGS) patients. DGS is marked by parathyroid
hypoplasia, thymic aplasia, or hypoplasia and cardiac abnormalities. Since DGS is a
developmental anomaly of the derivatives of the third and fourth pharyngeal pouches in
the embryo and Cdc45L is the first gene identified in the DGS critical region that is
required for cell division, deleting one copy may impair cell division during embryo
development leading to the abnormalities seen in DGS patients (28).
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The goals of this dissertation project were to understand how alterations in Cdc45
function affects cell sensitivity to DNA topoisomerase I poisons and to better understand
the function of Cdc45 as a component of replication complexes. Both of these goals were
achieved by characterizing the defects in the cdc45-10 mutant cells. First, a genetic
screen was developed to isolate dosage suppressors of cdc45-10 that allow cdc45-10 cells
to survive in the presence of DNA Top1 poisons. The essential function of Cdc45 in
initiation and elongation steps of DNA replication was also assayed by isolating
replication intermediates, then using two-dimensional gel electrophoresis to compare the
initiation of replication and the progression of replication forks in the mutant and wildtype cells. An antibody was also raised against S. cerevisiae Cdc45, to assess alterations
in protein levels and modifications that dictate differences between the Cdc45 mutant and
wild-type protein function.
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CHAPTER 2: GENETIC ANALYSIS OF cdc45-10

2.1 INTRODUCTION
Eukaryotic DNA topoisomerase I (Top1) plays a critical role in DNA replication,
recombination and transcription by catalyzing the relaxation of supercoiled DNA through
a mechanism of transient DNA strand cleavage and religation (1,2). Top1 is a monomeric
enzyme that forms a protein clamp around duplex DNA. The active site tyrosine (Tyr727
in yeast Top1) acts as a nucleophile to cleave the phosphodiester backbone of a single
DNA strand, forming a covalent 3’ phospho-tyrosyl linkage with the DNA. Within this
covalent Top1-DNA complex, the rotation of the 5’ DNA end about the nonscissile
strand relaxes the overwinding or underwinding of the DNA strands (positive or negative
supercoils, respectively). The 5’OH of the cleaved DNA strand acts as a nucleophile in a
second transesterification reaction to resolve the Top1-DNA intermediate and religate the
DNA (1,2).
Top1 is the sole cellular target of the anticancer agent camptothecin (CPT). CPT
targets Top1 by reversibly binding the covalent enzyme-DNA intermediate, which
prevents religation of the cleaved DNA. The stabilized drug-enzyme-DNA intermediates
are formed in all stages of the cell cycle; however, the cytotoxic activity of CPT is Sphase dependent. Two mechanisms have been advanced to explain the replicationdependent toxicity of camptothecins. First, biochemical and genetic data suggest
advancing replication forks collide with the stabilized CPT-Top1-DNA complexes to
induce irreversible DNA lesions that trigger checkpoint activation and cell death (6).
However, a recent study of camptothecin analog poisoning of human Top1 in a single
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molecule setting and in yeast cells suggests a distinct mechanism (8), whereby drug
binding of Top1-DNA complexes induces the accumulation of positive supercoils in front
of the moving replication fork. Such local domains of high superhelical density would
block fork progression, resulting in fork collapse and lethal DNA lesions that induce cell
death (8). However, despite extensive study, little is known of the molecular interactions
that convert the ternary Top1-DNA-CPT complexes into the DNA lesions that trigger
checkpoint activation or the downstream pathways required for the resolution and repair
of these lesions.
The budding yeast S. cerevisiae has proved an invaluable model for studies of
processes such as DNA replication and the mechanism of action of cancer therapeutics
(29). This genetically tractable microorganism has a genome of relatively low
complexity, exhibits high rates of homologous recombination and can be readily
transformed with mitotically stable plasmids. Mating of haploid strains of opposite
mating type to generate diploid cells, coupled with a sporulation program that allows the
recovery of all four meiotic products in a single ascus, underlies the facile genetics
necessary to elucidate complex cellular processes (29). Indeed, most basic cellular
processes and the cell cycle machinery are highly conserved from yeast to human, as are
the mechanisms of cell sensitivity and resistance to CPT. Yeast cells deleted for TOP1
(top1Δ) are viable due to the presence of other activities, such as that of DNA
topoisomerase II, which maintain cell viability. However, top1∆ strains are resistant to
CPT. Drug sensitivity can be restored by the expression of plasmid encoded yeast or
human Top1 (6). These studies establish Top1 as the cellular target of CPT, which
converts Top1 into a cellular poison.
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Alterations in the DNA cleavage-religation equilibrium of Top1, induced either
by drug binding or mutation of residues within the catalytic pocket of the enzyme, poison
Top1 by enhancing covalent complex stability. For example, mutation of Thr722 to Ala
in Top1T722A induces a decrease in the rate of DNA religation and acts as a CPT
mimetic. DNA repair and checkpoint proficient yeast cells can tolerate low-level
expression of this self-poisoning top1T722A mutant (5). Thus, this mutant allele provides a
valuable tool for identifying gene products and pathways that mediate cellular responses
to CPT, while avoiding the complications of drug uptake and efflux. As diagrammed in
Fig. 2.1, a genetic screen was designed to isolate conditional (temperature sensitive or ts)
mutants with enhanced sensitivity to Top1T722A, thereby identifying gene products that
act normally to protect cells against Top1-mediated damage.
In this screen, top1Δ cells, transformed with a plasmid that constitutively
expresses low levels of Top1T722A, were mutagenized with ethyl methanesulfonate
(EMS) and grown at 26°C. Following replica plating, colonies that were viable at 26°C,
but inviable at 36°C, were selected as potential tah (Top1T722A hypersensitive) mutants.
At 36°C, tah mutants were unable to survive damage induced by Top1T722A due to the
loss or decrease of TAH gene product function. To ensure that the phenotype of the tah
mutants was linked to top1T722A expression, the cells were first cured of the URA3
marked vector by successive replica plating on media containing 5-fluoroorotic acid (5FOA), then re-screened for growth at 36˚C. In the absence of Top1T722A, the top1∆, tah
mutants were viable at 36°C and cell growth was unaffected by the expression of Top1.
Extensive backcrossing of individual tah mutants with an isogenic wild-type strain
identified ten recessive mutants that defined nine complementation groups. The
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Fig. 2.1 Screen for Top1T722A hypersensitive (tah) mutants
Yeast cells deleted for TOP1 were transformed with a vector expressing low levels of
Top1T722A. The transformants were EMS mutagenized and plated at 26°C. Those
transformants that grew at 26° but failed to grow when plated at 36°C were isolated as
tah mutants. To ensure the temperature sensitivity was linked to Top1T722A, cells were
cured of the URA3 based plasmid using 5-FOA and re-screened for temperature sensitive
growth.
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corresponding wild-type TAH alleles were cloned by complementation using a low copy
vector-based yeast genomic DNA library. As summarized in Fig. 2.2, at the nonpermissive temperature, the tah mutants were also hypersensitive to CPT, when the cells
expressed wild-type Top1. The mutants also exhibited enhanced sensitivity to the
ribonucleotide reductase inhibitor hydroxyurea (HU), which further suggested defects in
DNA replication. The tah mutants exhibited varying levels of sensitivity to other DNA
damaging agents, such as the alkylating agent methyl methanesulfonate (MMS) and UV
light. The majority of TAH genes encode essential gene products, suggesting that the tah
mutants were hypomorphic. They also function in a surprising variety of cellular
processes. UBC9 encodes the sole SUMO E2 conjugating enzyme in yeast. DOA4
encodes a C-terminal ubiquitin hydrolase that functions to maintain ubiquitin
homeostasis. TAF47 (re-named TAF3) encodes a TATA binding protein that regulates
global transcription from the RNA polymerase II promoter. SLA1 encodes a cytoskeletal
binding protein required for the assembly of the cortical actin cytoskeleton. SLA2
encodes a transmembrane actin-binding protein involved in membrane cytoskeleton
assembly and cell polarization.
As diagrammed in Fig. 2.3, three of the TAH genes are essential for DNA
replication. CDC45 encodes a DNA replication initiation factor that is essential for the
initiation and elongation steps of DNA replication. DPB11 encodes a subunit of the DNA
polymerase II epsilon (ε) complex that is essential for the loading of DNA polymerases to
initiate DNA synthesis and is required for the S-phase checkpoint. TAH11 encodes a
DNA replication licensing factor required for pre-replicative complex formation (5). As
shown in Fig. 2.4, the tah mutant, cdc45-10, harbors a single mutation where Arg
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Fig. 2.2 TAH genes
TAH genes encoding essential gene products are depicted in bold print. TAH gene
products function in different cellular processes: DPB11, CDC45 and TAH11 encode
proteins that function in DNA replication, UBC9 encodes the sole E2 SUMO conjugating
enzyme, SLA1 and SLA2 encode gene products involved in cortical actin organization,
TAF47 (re-named TAF3) encodes a transcription factor component and DOA4 encodes a
ubiquitin hydrolase. The tah mutants are all hypersensitive to CPT and HU at 36°C and
some are also hypersensitive to MMA and UV light.
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Fig. 2.3 TAH gene function in DNA replication
Three of the TAH genes encode gene products that are essential for DNA replication.
Tah11 functions in pre-replicative complex formation, Cdc45 is required for the initiation
and elongation steps of replication and Dpb11 functions in polymerase switching and
checkpoint activation.
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Fig. 2.4 cdc45-10
The tah mutant cdc45-10 encodes a single missense mutation (G510R). The cells are
viable when TOP1 is present or deleted (top1Δ), however, cell viability is lost at 36˚C
when the cells express low constitutive levels of the CPT mimetic, Top1T722A.
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substituted for Gly510. With the exception of a bipartite nuclear localization signal, the
amino acid sequence of Cdc45 does not predict similarities with any known domains.
cdc45-10 cells are viable when either TOP1 is deleted or is expressed, however, the cells
are hypersensitive to Top1T722A expression at 36°C. cdc45-10 cells transiently
accumulate in early S-phase when shifted to 36°C due to a defect in Okazaki fragment
maturation. They also exhibit a slow growth phenotype when RAD9 is deleted
suggesting that damage accumulates and is sensed by the Rad9 DNA damage checkpoint.
Double mutant strains were constructed by combining the different tah alleles. The
combination of cdc45-10 with dpb11-10 resulted in a double mutant strain that was
inviable at 36°C in the absence of exogenous DNA damage. This synthetic lethal
interaction suggests that Cdc45 and Dpb11 share a common essential function. Because
Cdc45 is required for polymerase α loading and Dpb11 is a subunit of the DNA pol II ε
complex, which is required for DNA polymerase loading, the shared function of Cdc45
and Dpb11 could be switching between the pol α primase to the more processive
polymerases ε and δ.
Despite extensive study, the exact function of Cdc45 during the initiation and
elongation steps of DNA replication has yet to be defined. Our findings suggest that
Cdc45 functions normally to protect cells against Top1 induced DNA damage. However,
further characterization of the replication defects in cdc45-10 cells would provide
insights into the molecular interactions required for cellular resistance to Top1-induced
DNA damage. In this study, we report that cdc45-10 (cdc45G510R) is hypomorphic for
resistance to Top1T722A-induced DNA damage; however, this was not due to alterations
in Cdc45G510R protein levels. In contrast, increased expression of this mutant allele failed
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to suppress the synthetic lethality of cdc45-10,dpb11-10 cells, suggesting distinct effects
of the G510R substitution on Cdc45 function in response to Top1 poisons and it’s
interactions with Dpb11. These findings were further supported by the results of a yeast
genetic screen for dosage suppressors, which identified the SUMO E3 ligase, Siz1, as a
partial dosage suppressor of cdc45-10 cell sensitivity to Top1T722A, but not cdc4510,dpb11-10 synthetic lethality. Indeed, a cdc45 SUMO consensus site mutant also
exhibited a synthetic lethal interaction with dpb11-10, suggesting the functional
interaction of these replication proteins is facilitated by SUMO modification.

2.2 EXPERIMENTAL PROCEDURES

2.2.1 Chemicals, plasmids and yeast strains
Camptothecin, purchased from Sigma, was dissolved in dimethyl sulfoxide
(DMSO) and 4 mg/ml stock solutions were stored at -20˚C. Hydroxyurea (HU) and 5fluoroorotic acid (5-FOA) were obtained from U.S. Biological. 20T Zymolyase was
purchased from Seikagaku Corp.
Plasmids and yeast strains used in these studies are listed in Table 2.1 and 2.2,
respectively. Plasmids were amplified in Escherichia coli TOP10F’ cells (Invitrogen) and
purified using a kit from Qiagen. All mutations were confirmed by DNA sequencing. The
isogenic yeast strains were derived from FY250 (30). Where indicated, gene disruptions
were accomplished by PCR-based homologous recombination (31) and confirmed by
PCR of genomic DNA using primers that flanked the site of integration within the
genomic DNA. Primer sequences are available upon request.

29

Table 2.1 Plasmids
Plasmids
YCpSctop1T722A•U
YCpSctop1T722A•H
YEp24pL
YEp•FY250 genomic
DNA library
YEp•HCS81
YEp•HCS86
YCpCDC45
YEpCDC45
YCpcdc45-10
YEpcdc45-10
pAG60
pCLcdc45-10
pRS415
YCpCDC45•L

Characteristics

Reference

A 2.9-kb BamH1-XbaI fragment excised from
YCpGAL1top1T722A was ligated into YCpSc•U
CEN6/ARSH4; a 3.5-kb XhoI-NotI fragment of
top1T722A was excised from YCpSctop1T722A•U,
and ligated into the same site in pRS413
Modified YEp24 vector with multiple cloning site
of pBluescript
6-10kb genomic fragments were ligated into
partially Sau3A-digested DNA into
dephosphorylated BamHI ends of YEp24pl
Genomic fragment from YEp•FY250 genomic
DNA library inserted into the BamHI site of
YEp24pL
Genomic fragment from YEp•FY250 genomic
DNA library inserted into the BamHI site of
YEp24pL
CEN6/ARSH4;URA3; genomic fragment of
CDC45 cloned into pRS416.
2 µm; URA3; Not1-Sal1 fragment of YCpCDC45
cloned into YEp24pL.
CEN6/ARSH4; URA3; HindIII-SpeI fragment of
the cdc45G510R mutant from chromosome XII
ligated into pRS416.
2 µm; URA3; HindIII-SpeI fragment of
YCpcdc45-10 ligated into YEp24pL
TEF-promoter/terminator; C. albicans URA3
cassette
PvuII-HindIII fragment from YEpcdc45-10
cloned into pAG60.
CEN6/ARSH4; LEU2

(32)

pRS413

EagI-SalI fragment of CDC45 was excised from
YCpCDC45 and ligated into pRS415
NotI-HindIII fragment of pCLcdc45-10 was
excised and cloned into pRS415
CEN6/ARSH4; HIS3

pRS416

CEN6/ARSH4; URA3

YCpcdc45-10•L
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(32)
(33)
(34)
This work
This work
(22)
(22)
(22)
This work
(31)
This work
(35)
This work
This work
This work
(34)

Table 2.1 (continued)
Plasmids

Characteristics

pCLcdc45SUMO,G510R

Lys385 of pCLcdc45-10 was mutated to Arg using
oligonucleotide-directed mutagenesis
YCpCDC45-HA•L
CEN6/ARSH4; LEU2; CDC45-HA amplified
from CLY6 and cloned into pRS415 using EagI
and SalI
YCpcdc45-10-HA•L
CEN6/ARSH4; LEU2; EagI-PstI fragment of
YCpCDC45•L excised and ligated into
YCpCDC45-HA to create G510R mutation
pFA6a-3HA-His3MX6 Sequence encoding 3HA with S. cerevisiae
ADH1 terminator and the His3MX6 module
including the S. pombe his5+ gene
YCpCDC45SUMO•L
BstZ71I-NcoI fragment of pCLcdc45SUMO,G510R
was cloned into YCpCDC45•L
YCpcdc45SUMO,G510R•L BstZ71I-NcoI fragment of pCLcdc45SUMO,G510R
was cloned into YCpcdc45G510R•L
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Reference
This work
This work
This work
(36)
This work
This work

Table 2.2 Yeast strains
Strain

Genotype

Reference

EKY2

MATa, ura3-52, his3Δ200, leu2Δ1, trp1Δ63, top1Δ::HIS3

(22)

EKY3

MATα, ura3-52, his3Δ200, leu2Δ1, trp1Δ63, top1Δ::TRP1

(22)

RRY72-7

EKY3, cdc45-10

This work

RRY72-2

EKY2, cdc45-10

This work

RRY71-7

EKY3, dpb11-10

(22)

RRY81-1

EKY3, tah11-10

This work

RRY82

EKY3, ubc9-10

(32)

MSY18-6

EKY3, cdc45-10, dpb11-10

This work

PTY35

MATα, ura3-52, his3Δ200, leu2Δ1, trp1Δ63,
cdc45Δ::his5+, YCpCDC45
MATα, ura3-52, his3Δ200, leu2Δ1, trp1Δ63,CDC45 Cterminally tagged with HA using pFA6a-3HA-His3MX6

This work

CLY6
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This work

2.2.2 Yeast transformations
Lithium acetate treated yeast cells, transformed with URA3, LEU2, TRP1 or
HIS3-marked plasmids were selected on synthetic complete media lacking uracil (SCura), leucine (SC-leu), histidine (SC-his) or tryptophan (SC-trp), and supplemented with
2% (w/v) dextrose.

2.2.3 Cell viability assays
To assay cell sensitivity to Top1T722A, exponential cultures of cells transformed
with the indicated YCptop1T722A vector, were grown in selective media at 26°C,
adjusted to an O.D. = 0.3. Serial ten fold dilutions were then spotted in 5 µl aliquots onto
selective plates supplemented with dextrose. To assay cell sensitivity to HU, plates were
supplemented with 5 mg/ml HU. For CPT sensitivity, the agar plates were supplemented
with 25 mM HEPES (pH 7.2) and 0 or 5 μg/ml CPT in a final 0.125% DMSO. In all
cases, cell viability was assessed following incubation at 26˚C or 36˚C.

2.2.4 Isolation of dosage suppressors
cdc45-10 (RRY72) cells were co-transformed with YCpSctop1T722A•H and the
YEp-FY250 yeast genomic DNA library and selected on SC-ura,-his plates at 36˚C. To
ensure that cell viability at 36°C was due to the presence of the genomic DNA fragment
contained in the YEp plasmid, the cells were cured of the URA3-marked YEp plasmid by
successive replica plating of the transformants on SC-his plates supplemented with 5FOA. The resulting colonies were then replica plated onto SC-his plates and incubated at
36°C. For those colonies that were inviable at 36˚C, the YEp vector was then recovered
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from the original transformants for further characterization. Individual transformants,
grown in SC-ura at 26°C, were collected by centrifugation, washed with dH2O,
resuspended in 1M sorbitol, 20mMEDTA and treated with a freshly prepared solution of
20T zymolyase in 1M sorbitol at 37°C for 30 minutes. The spheroplasts were then
pelleted, resuspended in buffer P1 from the Qiagen miniprep kit and the plasmid DNA
was purified as per the manufacturer’s instructions. The purified plasmids were
subsequently amplified in E. coli TOP10F’ cells, and the DNA from individual
transformants were digested with XbaI and EcoRI to determine the size of the yeast
genomic DNA inserts. The restriction enzymes were chosen based on the restriction maps
of YCpCDC45, YCpSctop1T722A and YEp24pL. Digesting YCpCDC45 with XbaI and
EcoR1 yields a 1.4 kilobase (kb) fragment of CDC45 that was used as a control to
determine if any inserts in the plasmids were CDC45, whereas digests of
YCpSctop1T722A or YEp24pL served to distinguish Top1T722A and vector fragments
from vectors containing genomic DNA inserts. The restriction digests were resolved in
agarose gels and visualized by ethidium bromide staining using a BioRad Gel Doc
System. The high copy suppressor digests were compared to that of the vector controls to
determine the insert size. The recovered plasmids were verified by transformation with
YCpScTop1T722A into cdc45-10 cells. Individual colonies were picked and grown in
selective media at 26°C. Cell viability assays were used to access cell viability at 26°C
and 36°C. The high copy suppressor inserts were sequenced using T3 and T7 primers.
The DNA sequences obtained were used to query the Saccharomyces genome database
(SGD) and to identify the genomic DNA inserts.
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As each insert contained multiple reading frames, further subcloning determined
which open reading frame was responsible for the dosage suppression. YEp24-HCS86
was digested with EagI to excise 1.2 kb of the 5.5 kb insert, leaving the entire SIZ1 ORF
and 179 base pairs of the 644 base pair ADE8 gene. YEp24-HCS81 was digested with
SalI to excise the complete NDI1 gene including 140 base pairs upstream of the start
codon. This fragment was ligated into YEp24pl and the remainder of the digested
plasmid was religated. Each plasmid was co-transformed with YCpTop1T722A into
cdc45-10 cells and viability was accessed at 26°C and 36°C.

2.2.5 SUMO site mutations
Substitution of Arg for Lys385, in the consensus sumoylation site IK385RE of
Cdc45G510R, was accomplished by oligonucleotide-directed mutagenesis of pCLcdc4510 with the Quick Change Site-Directed Mutagenesis Kit (Stratagene) to generate
pCLcdc45SUMO,G510R , using the primer pairs
5’CATGGATCATTCTATTAGGAGAGAACTTGGG 3’ and 5’
CCCAAGTTCTCTCCTAATAGAATGATCCATG 3’. The DNA fragment spanning the
SUMO site mutant was then excised with BSTZ71I and Nco1 and ligated into the
corresponding sites in YCpCDC45•L and YCpcdc45-10•L, to generate
YCpCDC45SUMO•L and YCpcdc45SUMO, G510R•L, respectively.

2.2.6 Plasmid shuffle
To create the cdc45Δ plasmid shuffle strain (PTY35), wild-type FY250 cells were
transformed with YCpCDC45 and the genomic copy of CDC45 was replaced with the
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his5+ gene via PCR based homologous recombination (36). The primers used 5’
TAGAGAGAAGGCACATAATAACAAGAATATACTCTCGCACCGGATCCCCGGGTTA
ATTAA 3’ and
5’AATTTTGATTATAACAATCCACTCAAGGTCAGCTTCTCCAGGAATTCGAGCTCGT
TTAAAC 3’ contained 40 bases that were complementary to sequences flanking the 5’
and 3’ ends of CDC45 (in italics), respectively, while the remaining sequences are
complementary to plasmid sequences flanking the his5+ gene. YCpCdc45•L,
YCpCdc45SUMO•L, YCpcdc45-10•L and YCpcdcSUMO, G510R•L vectors were transformed
into the cdc45Δ strain and individual transformants were cured of the URA3-based vector
by successive replica plating on 5-FOA. Viable cells, containing only the LEU2 vectors,
were selected for further characterization.

2.3 RESULTS

2.3.1 cdc45-10 is a hypomorphic mutant
The tah screen for conditional mutants exhibiting enhanced cell sensitivity to
Top1 poisons (described in Fig. 2.1) generated temperature sensitive mutations in several
essential genes including CDC45, DPB11, TAH11 and UBC9. In the case of the ubc9-10
mutant, we reported that the mutant protein was thermolabile at 36˚C, as steady state
protein levels were reduced upon shift to the non-permissive temperature. The resultant
decrease in global SUMO conjugation sufficed to maintain cell viability at 36˚C yet
reduced cellular resistance to low levels of genotoxic stresses. These data indicated that
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the ubc9-10 mutant was hypomorphic, such that the mutant phenotypes resulted from a
decrease in Ubc9 function.
To assess whether the phenotypes ascribed to the cdc45-10 mutant were also a
consequence of a global decrease in Cdc45 function, we asked if increased copy number
of the cdc45-10 mutant allele would restore cellular resistance to low levels of
Top1T722A-induced DNA damage. To address this question, the entire coding region of
the cdc45-10 allele and the 5’flanking sequences necessary for gene expression were
cloned into a high copy 2µm-based vector. This vector was then co-transformed into
cdc45-10 mutant cells with YCpSctop1T722A•H or vector control. As shown in Fig. 2.5,
increased gene dosage of wild-type CDC45 or mutant cdc45-10 complemented the slow
growth phenotype exhibited by cdc45-10 cells in the absence of DNA damage as well as
the Top1T722A-induced cell lethality at 36˚C. These data suggest that cdc45-10 is
hypomorphic for the defects necessary to protect cells from low levels of Top1-induced
DNA damage.
These data contrasted with the inability of YEpcdc45-10 to dosage suppress the
synthetic lethal interactions of cdc45-10 with dpb11-10. As shown in Fig. 2.6, while
increased dosage of wild-type CDC45 complemented the lethal phenotype of the cdc4510,dpb11-10 strain at 36˚C, YEpcdc45-10 failed to restore viability. These results raise
two possibilities. First, there are distinct functions for Cdc45, one required to protect cells
from low levels of S-phase DNA damage and another for the functional interaction with
Dpb11. Alternatively, a lower threshold of Cdc45 function may be necessary for cellular
resistance to Top1T722A in wild-type DPB11 cells, while higher levels of Cdc45 activity
is needed to maintain cell viability when both Cdc45 and Dpb11 function is altered.
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Fig. 2.5 Increased gene dosage of cdc45-10 restores cellular resistance to Top1T722A
cdc45-10 cells were co-transformed with CDC45 or cdc45-10 vectors and Top1T722A.
Expression of CDC45 (low copy or high copy) and high copy expression of cdc45-10
restores cell viability to cdc45-10 cells in the presence of Top1T722A at 36˚C.
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Fig. 2.6 Increased expression of cdc45-10 does not restore cell viability to the cdc4510, dpb11-10 double mutant strain
The cdc45-10, dpb11-10 double mutant strain was transformed with vectors expressing
low or high levels of CDC45 or a vector expressing high levels of cdc45-10. Low or high
level expression of CDC45 (YCpCDC45 or YEpCDC45) was able to restore cell viability
to the double mutant strain at 36˚C, however, increased expression of cdc45-10
(YEpcdc45-10) was not able to restore cell viability at 36˚C.
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2.3.2 Epitope tagging of Cdc45 and Cdc45G510R
To address these questions, and the basis for the hypomorphic phenotype of
cdc45-10 itself, we attempted to incorporate an epitope tag into the genomic copy of
CDC45 and cdc45-10. This approach, of introducing a C-terminal HA tag into wild-type
Cdc45, has been extensively used to characterize Cdc45 protein levels, interactions with
other proteins and chromatin association (16,23-26,37,38). Thus, we anticipated this
approach would be a relatively straightforward means of incorporating an epitope tag into
Cdc45G510R. However, this was not the case. As summarized in Fig. 2.7, several
approaches were taken. First, we attempted to introduce a hemagglutinin (HA) or Myc
epitope tag at the C- terminus of Cdc45 and cdc45G510R by integrating sequences
encoding these tags into the genome of haploid yeast strains using PCR-based
homologous recombination. While this method was successful for CDC45 it was
unsuccessful for cdc45G510R. In both cases, viable HIS+ cdc45-10 colonies were not
recovered. Related attempts to recover an N-terminal HA-cdc45-10 strain also failed. As
diagrammed in Fig. 2.7, these findings suggest that incorporating an epitope tag at either
the N- or C-terminus of Cdc45G510R further impairs protein function such that the cells
are no longer viable.
To further investigate this possibility, CDC45-HA was amplified from genomic
DNA and cloned into YCpCDC45-HA. A DNA fragment of cdc45G510R that contained
the nucleotide sequence coding the G510R mutation was then ligated into YCpCDC45-HA
to create YCpcdc45-10-HA. The tagged and untagged versions of these vectors were then
shuffled into the cdc45Δ (TOP1 and top1∆) strains (as depicted in Fig. 2.8) and the
ability of each cdc45 allele to maintain cell viability was assayed. As shown in Fig. 2.9,
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Fig. 2.7 Epitope tagging of Cdc45 and cdc45-10
A HA tag was incorporated at the C-terminus of CDC45 using PCR based homologous
recombination. However, incorporating a HA or Myc tag at the C or N-terminus of
cdc45-10 resulted in a protein that was not able to maintain cell viability.
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Fig. 2.8 Plasmid shuffle
Cells were transformed with a URA3 vector carrying wild-type CDC45. The genomic
copy of CDC45 was deleted and replaced with HIS5+. The deleted strain was
transformed with LEU2 vectors carrying the Cdc45 mutations to be assayed and cured of
the URA3 vectors using 5-FOA. The cells carrying the LEU2 vectors were assayed for
cell viability.
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Fig. 2.9 Plasmid shuffle of untagged or C-terminally HA tagged CDC45 and cdc4510
Vectors expressing C-terminally tagged or untagged CDC45 or cdc45-10 were shuffled
into a cdc45Δ strain. CDC45, CDC45-HA and cdc45-10 were able to maintain cell
viability while cdc45-10-HA was not able to maintain cell viability.
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each of the untagged constructs and YCpCDC45-HA maintained cell viability, whereas
cells containing YCpcdc45-10-HA as the sole source of Cdc45 were inviable. These
results were independent of Top1. Moreover, they could not be ascribed to a decrease in
protein function, as increased dosage of the cdc45-10-HA allele on a high copy YEp
vector also failed to maintain cell viability (data not shown). In parallel, attempts to
recover haploid cdc45-10-HA cells from heterozygous diploids following sporulation and
tetrad dissection were also unsuccessful (data not shown). Taken together, these data
demonstrate that the introduction of a C-terminal epitope tag into Cdc45G510R induces a
null phenotype, consistent with a more severe defect in Cdc45 function.
These results also questioned the effects of the C-terminal HA tag on wild-type
Cdc45 function. The cdc45-10,dpb11-10 double mutant strain is inviable at 36°C in the
absence of exogenous DNA damage. Thus, to determine if incorporating a C-terminal
epitope alters wild-type Cdc45 protein function, YCpCDC45-HA and YCpcdc45-10-HA
vectors were transformed into the cdc45-10,dpb11-10 double mutant strain and cell
viability was assessed at 26°C, 30°C and 36°C. As shown in Fig. 2.10, YCpCDC45-HA
and YCpcdc45-10-HA transformants exhibited a slow growth phenotype at 30°C, while
neither vector restored cdc45-10,dpb11-10 cell viability at 36˚C. These findings suggest
that incorporating an HA tag at the C-terminus of Cdc45 alters normal protein function,
including that required to suppress the synthetic lethal interaction with dpb11-10.
Although modifying the C-terminus of the protein induced interesting alterations in
Cdc45 function, this strategy failed to provide a means of assessing Cdc45 protein levels
in vivo. Therefore, we next attempted to generate peptide-based polyclonal antibodies. As
shown in Fig. 2.11, several peptides were generated and used as antigens in rabbits. The
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Fig. 2.10 The cdc45-10,dpb11-10 double mutant strain transformed with untagged
and HA tagged Cdc45 vectors
The cdc45-10,dpb11-10 strain was transformed with vectors expressing CDC45, CDC45HA, cdc45-10 and cdc45-10-HA and cell viability was assessed at 26˚C, 30˚C and 36˚C.
YCpCDC45-HA and YCpcdc45-10-HA exhibit a slow growth phenotype at 30˚C, while
neither vector can restore cell viability to cdc45-10,dpb11-10 at 36˚C.
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Fig. 2.11 Peptides used to generate S. cerevisiae Cdc45 polyclonal antibodies
Two antigens were used to immunize rabbits to produce a S. cerevisiae polyclonal Cdc45
antibody. The peptide spanning amino acid region 444-457 failed to recognize Cdc45
while the peptide spanning amino acid region 196-212 recognize the 74 kDa band
corresponding to Cdc45.
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resulting antibodies were purified on peptide-coupled resins as described (39). The
antibody generated against the peptide spanning amino acids 444-457 failed to recognize
Cdc45 in western blots of whole cell extracts. A second peptide, spanning amino acids
196-212, was also used based on discussions with Bruce Stillman’s lab. This
antibody recognized the 74 kilo dalton (kDa) band corresponding to Cdc45, which was
confirmed in western blots of Cdc45-HA and in immunoprecipitations of Cdc45-HA
proteins immunoblotted with our Cdc45 polyclonal antibody.

2.3.3 Steady state levels of Cdc45G510R are unaltered at 36˚C
As shown in Fig. 2.12, the steady state levels of Cdc45G510R protein obtained
from crude extracts of asynchronous cells grown at the permissive (26˚C) or nonpermissive temperature (36˚C) mirrored those of wild-type Cdc45. Thus, unlike the
dramatic decrease in Ubc9P123L protein levels induced upon shifting the tah mutant ubc910 to the non-permissive temperature, the hypomorphic phenotype of cdc45-10 cells
could not be attributed to the down regulation of a thermolabile protein. Although
CDC45 gene expression is cell cycle regulated, Cdc45 protein levels have been reported
to be constant throughout the cell cycle. Thus, the G510R mutation did not appear to alter
mutant protein levels in exponentially growing cells, either in the presence or absence of
Top1.

2.3.4 High copy suppressors of cdc45-10
As the increased gene dosage of cdc45-10 suppressed the hypersensitivity of these
cells to Top1T722A, but not the synthetic lethality of cdc45-10,dpb11-10 cells, we posited
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Fig. 2.12 Steady state protein levels of CDC45 and cdc45-10 asynchronous cultures
Steady state protein levels of Cdc45 and cdc45-10 at 26˚C and 36˚C were visualized by
western blots using the Cdc45 polyclonal antibody. In both, CDC45 and cdc45-10, there
is an increase in protein levels at 36˚C compared to 26˚C.

48

that a yeast genetic screen for extragenic dosage suppressors of cdc45-10 would further
define pathways specific for cellular resistance to Top1 poisons. As shown in Fig. 2.13,
cdc45-10 cells were co-transformed with two vectors: a low copy ARS/CEN vector
expressing Top1T722A from a weak constitutive promoter and a high copy (~50-200
copies/cell) URA3-marked YEp vector containing random fragment of yeast genomic
DNA. The transformants were selected for viability at the non-permissive temperature,
36°C. To ensure that cell viability at 36°C was due to the presence of increased copies of
a gene(s) in the YEp vector, the transformants were first patched onto SC-leu plates at
26˚C, then successively replica plated onto SC-leu media supplemented with 5-FOA.
Only cells that have lost the YEp-genomic DNA vector, yet retained the Top1T722Aexpressing vector would be viable under these conditions. These cells were then
examined for Top1T722A-induced lethality at 36˚C. The YEp library plasmid was isolated
from the original 26°C transformants that met these criteria and rescreened for gene
dosage suppression of cdc45-10. Two high copy suppressors (HCS81 and HCS86) were
isolated and identified by querying the Saccharomyces Genome Database (SGD) with
DNA sequences obtained from the 5’ and 3’ ends of the inserts. As shown in Fig. 2.14,
HCS81 contains a fragment of chromosome XIII, with two complete open reading frames
(ORFs), two partial ORFs and an origin of replication, ARS 1303. Of the complete
ORFs: NDI1 encodes a NADH-ubiquinone oxidoreductase and YML119W encodes a
protein with unknown function. The two partial ORFs are GTR1 and NGL3. Based on
annotated sequences obtained from the SGD, subsequent restriction digestion and
subcloning of the individual ORFs in HCS81 failed to define any of the ORFs as a dosage
suppressor of top1T722A-induced cdc45-10 cell lethality at 36˚C (data not shown). Rather,
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Fig. 2.13 Isolation of dosage suppressors of cdc45-10
cdc45-10 cells were co-transformed with Top1T722A and a high copy yeast genomic
library, plated and grown at 36°C. The transformants that were viable at 36°C were
cured of the library plasmid using 5-FOA to ensure the viability 36°C was due to the
presence of the library plasmid. The plasmids were isolated, sequenced to identify the
high copy suppressor fragment and re-screened for resistance to Top1T722A.
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Fig. 2.14 Dosage suppressors of cdc45-10 complement other tah mutant cell
sensitivity to Top1T722A
HCS86 contains two complete ORFs and one partial ORF. When digested the fragment
containing SIZ1 was responsible for the suppression of cdc45-10 and ubc9-10 in the
presence of Top1T722A at 36°C. HCS81 contains two complete ORFs, two partial ORFs
and the origin ARS1303. HCS81 restores cell viability to cdc45-10, dpb11-10 and tah1110 in the presence of Top1T722A at 36°C.
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the presence of an additional origin of replication, ARS1303, in the YEp vector appeared
to partially suppress the inability of cdc45-10 cells to grow on SC-leu,-ura (data not
shown).
Previous studies of conditional tah11 mutants suggested that a defect in origin
licensing by Tah11 results in the preferential loss of ARS/CEN vectors, due to diminished
plasmid replication resulting in plasmid instability. However, this defect in plasmid
mitotic stability could be suppressed by the presence of multiple ARS elements on a
single vector, thereby increasing the likelihood that at least one origin would fire per cell
cycle. The identification of ARS1303 as a dosage suppressor of cdc45-10 led us to
consider that a defect in origin firing in these cells might render the YEp vectors unstable,
thereby contributing to the inability of these cells to grow on SC-ura media. If so, then
this vector should also act as a partial HCS of tah11-10 cells. Indeed, of all the tah strains
surveyed, HCS81 only suppressed the Top1T722A-hypersenitivity of cdc45-10, dpb11-10
and tah11-10 strains (Fig. 2.14), consistent with a defect in the licensing and/or firing of
origins for replication.
The second dosage suppressor, HCS86 contains two complete ORFs and one
partial ORF (Fig. 2.14). The complete ORFs are ADE8, which encodes a protein involved
in adenine biosynthesis and SIZ1, which encodes a SUMO E3 ligase. The partial ORF is
TRS120. Subcloning of HCS86 determined that a DNA fragment containing SIZ1 and a
portion of ADE8 sufficed to partially restore cdc45-10 cellular resistance to Top1T722Ainduced DNA damage (data not shown). As with HCS81, the ability of HCS86 to dosage
suppress the Top1T722A-dependent lethality of the other tah mutants was also assessed.
However, in this case, only ubc9-10 cell viability was enhanced by HCS86 (Fig. 2.14).
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Because HCS81 and HCS86 restored cell viability to different tah strains, they
were independently transformed into the cdc45-10, dpb11-10 strain to determine if they
could complement the temperature-sensitive phenotype of the double mutant at 36°C. As
shown in Fig. 2.15, neither restored cell viability at 36°C. These findings further support
the notion that the cdc45-10 defect responsible enhanced cell sensitivity to Top1T722A is
distinct from the synthetic lethal interactions of cdc45-10 with dpb11-10.

2.3.5 SUMO modification of Cdc45
The isolation of SIZ1 as a high copy suppressor of cdc45-10 suggested that
increased SUMO modification of a protein or proteins could alter cell sensitivity to Top1
poisons. As diagrammed in Fig. 2.16, SUMO (small ubiquitin-like modifier) in
mammalian cells or Smt3 in yeast is activated when a peptide tail is removed by the Ulp1
protease to yield a mature di-Gly C terminus. A highly conserved SUMO E1 enzyme
(Aos1/Uba2) initiates conjugation by first adenylating SUMO and then forming a
covalent thioester bond between the C-terminus of SUMO and the active site Cys of the
E1. The E1 then transfers SUMO to the catalytic Cys of the sole SUMO E2 conjugating
enzyme, Ubc9. Next, either Ubc9 alone or in association with an E3 ligase (such as Siz1,
Siz2, or Mms21) catalyzes the formation of an isopeptide linkage between the C-terminal
carboxyl group of SUMO and the ε-amino group of the lysine in the target protein.
Substrates can be de-SUMOylated by the action of the proteases Ulp1 or Ulp2.
Modification of a target protein by SUMO can alter the protein’s subcellular localization,
activity, stability or interactions with other proteins, to affect cellular processes such as
gene transcription, apoptosis, cell cycle progression, chromatin organization and DNA
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Fig. 2.15 Dosage suppressors of cdc45-10 are not able to restore cell viability to the
cdc45-10, dpb11-10 double mutant strain at 36°C
HCS81 and HCS86 were transformed into the cdc45-10, dpb11-10 double mutant strain
and cell viability was assayed. Neither high copy suppressor could restore cell viability to
the double mutant strain at 36°C.
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Fig. 2.16 SUMOylation cycle
SUMO is expressed as an inactive protein that becomes active when the protein tail is
removed by the protease Ulp1. Active SUMO binds to the E1which transfers it to the E2,
Ubc9. Ubc9 alone or with the help of an E3 conjugates SUMO to the lysine of the target
protein. Target proteins can be de-sumoylated by the proteases Ulp1 or Ulp2.
SUMOylation of a protein can affect protein localization or conformation, complex
formation or protect from ubiquitin degradation.
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repair. Ubc9 itself contains determinants of SUMO target recognition and binds directly
to a consensus ΨΚX(D/E) motif, where Ψ is a hydrophobic residue, X is any amino acid
and K is the lysine modified with SUMO. However, this specificity of Ubc9 is
insufficient to account for the increasing number of SUMOylated proteins that are being
reported and modification of nonconsensus SUMO sites has also been reported (32). An
added complication of the analysis of protein SUMOylation is the transient nature of the
SUMO linkage. For most targets, considerably less than 10% of the protein is modified at
any given time, which makes SUMO target identification extremely difficult.
The ability of SIZ1 to dosage suppress ubc9-10 sensitivity to Top1-induced DNA
damage (32) was not surprising, as we had previously reported a decrease in global
SUMO conjugation in ubc9-10 cells shifted to the non-permissive temperature (30).
However, the results obtained with cdc45-10 cells prompted us to consider Cdc45 as a
potential target of SUMOylation. Indeed, inspection of the primary amino acid sequence
of S. cerevisiae Cdc45 revealed a consensus SUMO site located at Lys385. To assess if
this site was an important determinant of temperature or drug sensitivity, CDC45 and
cdc45-10 sequences were mutated, such that Arg was substituted for Lys 385. Vectors
bearing wild-type CDC45, cdc45-10 and the corresponding SUMO mutants, cdc45SUMO
and cdc45SUMO,G510R, respectively, were used in a plasmid shuffle in a cdc45Δ strain, as
previously depicted in Fig. 2.8 and the effects of mutating K385 on cell sensitivity to
high temperature, HU or CPT was assayed. As shown in Fig. 2.17, the viability of cells
expressing cdc45SUMO versus Cdc45 was unaffected by high temperature (36°C) or
exposure to HU or CPT at 36°C. In contrast, expression of cdc45SUMO,G510R further
enhanced the slow growth phenotype and hypersensitivity to HU and CPT induced by
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Fig. 2.17 Mutating the consensus SUMO site in Cdc45 enhances cdc45-10, but not
CDC45, cell sensitivity to CPT or HU
Cdc45, cdc45SUMO, cdc45-10 and cdc45SUMOG510R were shuffled in to the cdc45Δ
plasmid shuffle strain and cell viability was assayed. Mutating the consensus SUMO site
in Cdc45 did not alter cell sensitivity to CPT or HU. However, mutating the consensus
SUMO site in cdc45-10 enhanced temperature sensitivity and sensitivity to CPT and HU.
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cdc45-10 at 36˚C. These results suggest that mutation of the consensus SUMO site in
Cdc45 does not alter cell sensitivity to CPT or HU; however, substitution of this Lys
residue potentiates the defects in Cdc45G510R function responsible for the tah phenotype
of cdc45-10 cells at 36°C.
We next asked if the SUMO site mutation had any impact on the synthetic
lethality of the double cdc45-10, dpb11-10 mutant. The vectors were transformed into
cdc45-10, dpb11-10 cells and the viability of individual transformants was assayed at
26°C and 36°C. As shown in Fig. 2.18, cdc45SUMO was not able to complement the
synthetic lethal interactions of cdc45-10 and dpb11-10, suggesting that SUMO
modification is required for the functional association of Cdc45 with Dpb11.

2.4 DISCUSSION
Cdc45 plays essential roles in DNA replication, both in the initiation of DNA
replication and in processive DNA polymerization. In addition to recruiting replication
factors necessary for origin firing, Cdc45 also acts as a processivity factor for the
replicative Mcm2-7 helicase. Indeed, chromatin immunoprecipitation of crosslinked
Cdc45-DNA complexes, followed by queries of high density tiling arrays of yeast
chromosome VI, demonstrate that Cdc45 is associated with ARS sequences in G1 phase
of the cell cycle, yet tracks with the replication fork following origin firing. We
previously reported that Cdc45 also plays a role in protecting cells from low levels of
DNA damage induced by the CPT mimetic, Top1T722A. The conditional cdc45-10
mutant harbors a single amino acid substitution, G510R, and is hypersensitive to CPT, HU
and UV at 36°C. Upon shift to 36˚C in the absence of DNA damage, these cells exhibit a
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Fig. 2.18 Cdc45SUMO did not restore cell viability to the cdc45-10, dpb11-10 double
mutant strain
Cdc45, cdc45SUMO, cdc45-10, cdc45SUMOG510R plasmids were transformed into the
cdc45-10, dpb11-10 double mutant strain and cell viability was assayed at 26˚C and
36˚C. cdc45SUMO, cdc45-10 or cdc45SUMO, G510R was not able to restore cell viability to
the double mutant strain at 36°C.
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transient defect in Okazaki fragment maturation. We previously reported that this mutant
also exhibits a synthetic lethal interaction with another tah mutant, dpb11-10, which
coincides with a persistent accumulation of Okazaki sized DNA fragments. The cdc45-10
mutant also exhibits a slow growth phenotype when RAD9 is deleted suggesting that the
damage accumulating in cdc45-10 cells is sensed by the Rad9 DNA damage checkpoint.
Indeed, this mutant also exhibits synthetic lethal interactions with mrc1∆ and rad52∆
(data not shown), which is consistent with defects in processive DNA polymerization that
require the Mrc1 checkpoint and homologous recombination for effective resolution of
the Okazaki fragments.
In these studies, we provide direct evidence that cdc45-10 is hypomorphic for
cellular resistance to Top1-induced DNA damage, as increased gene dosage of the mutant
allele restored cell resistance to low levels of Top1-DNA damage as well as the slow
growth of this mutant at 36˚C. However, as cdc45-10 failed to dosage suppress the
synthetic lethality of cdc45-10,dpb11-10 cells, these findings support a model whereby
the functional interactions that are essential to maintain cell viability and Okazaki
fragment maturation are distinct from the activity of Cdc45 needed to protect cells from
Top1 poisons. Indeed, the results of the genetic screen for HCS of cdc45-10 cell
sensitivity to Top1T722A also demonstrated that HCS81 and HCS86 failed to complement
the temperature sensitive lethality of cdc45-10, dpb11-10 cells. An alternative
explanation is that the shared defect in cdc45-10,dpb11-10 cells is more severe than that
of cdc45-10 in the presence of wild-type DPB11, ergo the synthetic lethal phenotype.
However we favor the former interpretation since mutation of Lys385 within the
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consensus SUMO site in Cdc45 abolished cdc45-10,dpb11-10 cell viability, yet had no
effect on cell sensitivity to Top1T722A or cell growth.
Our attempts to develop epitope tagged versions of the Cdc45G510R mutant
protein with which to assess alterations in Cdc45 levels, chromatin association, proteinprotein interactions, and subcellular distribution were unsuccessful. Nevertheless, these
experiments clearly demonstrated that the C-terminal modifications of Cdc45G510R
completely abrogated the essential function of this protein. These findings indicate a
functional interaction between the C-terminus of Cdc45 and residues spanning Gly510.
Since Gly is a very flexible amino acid, it is tempting to speculate that a change in protein
architecture induced by the loss of Gly at this position is responsible for the tah
phenotype of cdc45-10 cells. However, such considerations of mutant protein function
will have to await the X-ray structure of Cdc45.
The analysis of wild-type Cdc45 bearing a C-terminal HA tag also revealed some
surprises. Although such constructs have been used extensively to assess Cdc45
association with chromatin and it’s association with other cellular components, we found
that Cdc45-HA was unable to suppress the synthetic lethality of cdc45-10,dpb11-10,
while untagged Cdc45 did. These data demonstrate that the C-terminal HA residues
altered the activity of Cdc45 in vivo. Moreover, these data raise the distinct possibility
that additional functions for Cdc45 may yet be defined that are abolished or diminished in
strains expressing Cdc45-HA. While the peptide-based antibodies generated in these
studies were useful in assessing Cdc45 proteins in westerns blots, they proved ineffective
in immunoprecipitation experiments. Thus, questions concerning alterations in mutant
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Cdc45 interactions with Dpb11, Mcm5 or other components of the replication machinery
will require the generation of additional antibodies.
The isolation of HCS81 and HCS86 as dosage suppressors of cdc45-10 cell
sensitivity to Top1T722A suggested specific defects in Cdc45G510R function. First, our
determination that ARS1303 was responsible for the dosage suppression induced by
HCS81 suggests a defect in origin licensing or firing in cdc45-10 cells. Indeed, the
presence of two origins of replication (2µm and ARS1303) in the URA3 marked YEp
vector also partially suppressed the tah phenotype of dpb11-10 and tah11-10. Since
CDC45, DPB11 and TAH11 each provide essential functions in the initiation of
replication, these findings suggest the mutants are defective in the replication and,
therefore, the maintenance of plasmid DNA. The presence of an additional ARS may
increase the likelihood of at least one origin firing per cell cycle. The temporal pattern
and efficiency of ARS firing on yeast chromosome III have been well characterized.
However, considerably less is known about ARS1303. Other ARS sequences were not
isolated in our yeast HCS screen. Although the screen was not saturated, the sole
isolation of ARS1303 raises the possibility that a unique feature of ARS1303 may be
critical for this dosage suppression. Some origins, such as ARS305 fire early and
efficiently in S-phase, while ARS309 fires late. ARS301 is a cryptic origin that only fires
in Rad53 checkpoint defective strains exposed to DNA damaging agents. Whether any or
all of these ARS sequences would also act as dosage suppressors of cdc45-10 or if
ARS1303 function is uniquely enhanced by the defects in cdc45-10, tah11-10 or dpb1110 cells have yet to be defined.

62

In the case of HCS86, the ability of the SIZ1 to restore cdc45-10 or ubc9-10 cell
viability in the presence of Top1T722A at 36°C suggests that SUMOylation of specific
target proteins is required to protect cells from Top1 poisons. While mutation of the
Cdc45 SUMO consensus site (Lys385) did not alter cell sensitivity to CPT or HU at 36°C,
this mutation in the context of cdc45-10 enhanced the temperature sensitivity and CPT
and HU sensitivity of these cells at 36°C. Moreover, Cdc45SUMO was not able to restore
cdc45-10,dpb11-10 cell viability, suggesting that SUMO modification of Cdc45 is a
critical determinant of the functional interaction of Cdc45 and Dpb11.
Mutations in genes that encode proteins involved in the SUMO pathway have also
been shown to induce cell cycle defects (40). For instance, yeast Smt3 (SUMO) was first
identified in a screen for high copy suppressors of mutants of MIF2, which encodes a
centromere binding protein. SUMO E1 (uba2-ts) and ubc9-ts mutants exhibit cell cycle
defects and arrest at the G2/M boundary. On the other hand, SUMO modification of
target proteins is typically very transient, such that only a small percentage of a given
protein is SUMOylated at any one time. Thus, sensitive detection methods are often
employed to ascertain whether a specific protein is actually SUMOylated, under a limited
set of experimental conditions. Several large-scale proteomic analyses have identified
SUMO substrates that are involved in many cellular processes including cell cycle, DNA
replication, repair and recombination. For example, PCNA, the DNA polymerase sliding
clamp, is SUMOylated in a cell cycle regulated manner, suggesting this modification is
important for events occurring S-phase (41). SUMOylation of PCNA in response to DNA
damage also promotes error-prone synthesis through recruitment of a translesion
polymerase (42). DNA topoisomerase I itself has been shown to be modified by SUMO,
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however, the consequence of this modification is debatable (30). Although our data
implicate SUMOylation as a determinant of Cdc45 function, we have yet to ascertain
whether Cdc45 itself is modified, or if SUMO conjugation of other replication proteins
indirectly impacts the function of Cdc45 is protecting cells from Top1 poisons.
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CHAPTER 3: CDC45 ORIGIN FIRING AND REPLICATION FORK
PROGRESSION

3.1 INTRODUCTION
DNA replication is fundamental for the maintenance and growth of eukaryotic
organisms (43). Chromosomal DNA must be replicated once and only once during
S-phase to ensure the faithful transmission of genetic information to daughter cells (12).
DNA replication is a complex process involving stringent regulatory mechanisms that
couple replication to cell cycle progression (11). Failure to coordinate replication with
cellular pathways such as cell cycle progression, checkpoints, recombination, repair and
sister chromatid cohesion could result in chromosomal lesions or mutations leading to
genomic instability, cell death or cancer (12).
The budding yeast, Saccharomyces cerevisiae, has been proven to be a
particularly tractable model system for identifying components of the DNA replication
machinery due to the distinctive growth patterns that allow cell division cycle (cdc)
phenotypes to be easily distinguished from defects in other cellular processes (44). In S.
cerevisiae, DNA replication is initiated at restricted regions called autonomously
replicating sequences (ARS). As diagrammed in Fig. 3.1, the six-subunit origin
recognition complex (ORC) binds ARS throughout the cell cycle. At the end of mitosis
the pre-replicative complex (pre-RC) consisting of the Mcm2-7 complex, Cdc6 and
Tah11binds to ARS, licensing cells for DNA replication. As cells transition through late
G1 phase, Cdc45 binds to the Mcm2-7 complex. As the pre-RC and initiation complexes
are assembled, the cyclin dependent kinases, Cdc28/Clb5/Clb6 and Cdc7/Dbf4, become
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Fig. 3.1 DNA replication
At the end of mitosis a decrease in Cdk-Clb kinase activity allows pre-replicative
complex formation consisting of Orc, Mcm2-7, Tah11 and Cdc6. Cells pass through
“START” in G1-phase committing them to DNA replication. As cell begin to transit from
late G1 to S-phase Dbf4-Cdc7 and Clb5/6-Cdc28 protein kinases become active and
phosphorylate components of the pre-RC promoting the recruitment of Cdc45 and GINS.
Once DNA replication is initiated, Dpb11 recruits Pol ε and facilitates the switch between
Pol α and Pol ε. Mcm2-7, GINS and Cdc45 move with replication forks as elongation
occurs.
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active and phosphorylate components of the pre-RC and Cdc45 resulting in stable
protein-protein interactions (45). In particular, the binding of the GINS complex
stabilizes the association of Cdc45 with Mcm2-7 to facilitate the processive activity of
the replicative helicase during the elongation phase of DNA replication.
Cdc45 is an essential protein that is required for the initiation and elongation steps
of DNA replication. The binding of Cdc45 to the Mcm2-7 complex at the origin is a
critical event for origin firing. Following Cdc45 binding and initiation of replication, the
origin DNA unwinds allowing the replicative machinery to bind and synthesis to
progress. The initial step in elongation is the synthesis of a short RNA primer laid down
by Polα primase. Polα is then replaced with the more processive polymerases delta (Δ)
and epsilon (ε) through the action of PCNA, the “sliding clamp” processivity factor and
replication factor C (Rfc), the clamp-loading complex. DNA is synthesized as leading
and lagging strands. Leading strand synthesis is very efficient and highly processive,
while lagging strand synthesis requires multiple cycles of priming and extension.
Lagging strand synthesis results in Okazaki fragments that must be processed by
nucleases and DNA ligase to create a single DNA chain. To protect the underlying DNA
and ensure completion of DNA synthesis, leading and lagging strand synthesis remains
coupled throughout synthesis (10).
Two-dimensional neutral/neutral gel (2-D gel) electrophoresis has been
extensively used to describe the conformational changes that occur in replication
intermediates during the initiation and elongation steps of DNA replication (12). This
method was derived by analyzing circular DNA on agarose gels and demonstrated that
different shapes of a DNA molecule influences its electrophoretic mobility. Supercoiled
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and nicked circular DNA have mobilities that differ from linear molecules of the same
mass. Branch molecules also run irregularly in agarose gels and this is influenced by the
agarose concentration and the strength of the electric field (46). Based on these
properties, Bell and Byers developed the 2D agarose gel method to separate linear
molecules from branched intermediates (47). The first dimension gel is run under
conditions that minimize the effect of molecular shape and separates molecules according
to their mass. The second dimension gel is run under conditions that emphasize the effect
of shape and separates the molecules accordingly (46,48).
The first step in analyzing replication intermediates in 2D gels involves enriching
the samples with replication intermediates by synchronizing the cells in G1 phase and
harvesting the DNA during S-phase. The DNA molecules isolated are delicate branched
molecules and precautions must be taken in order to preserves the integrity of the DNA at
the fork. As described in Fig. 3.2, the genomic DNA is digested with restriction enzymes
to create fragments specific to the chromosomal regions of interest. These fragments are
run in a low percentage first dimension gel. The portion of the first dimension gel
containing the restriction fragments of interest is cut, rotated 90° and embedded in a
higher percentage agarose second dimension gel. Electrophoresis is carried out in the
presence of ethidium bromide to aid in separating the shapes of the replication
intermediates. Following electrophoresis, the gel is subjected to Southern blotting and the
membrane is hybridized with a 32P labeled probe in order to visualize the replication
intermediates at origins or surrounding chromosomal regions of interest (46). Fig. 3.3
diagrams the shapes of restriction fragments derived from replicating DNA. The 1n spot
located on the linear molecule line represents non-replicating molecules. Replication
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Fig. 3.2 Replication intermediate isolation and viualization by 2-D gel
electrophoresis
Cells are synchronized in early G1 and released into S-phase. Genomic DNA is extracted
from replication intermediates, restriction digested with HindIII and EcoRV and
separated by size in the first dimension. Fragments of 3.5 Kb and larger are excised from
the first dimension, rotated 90˚, and separated in the second dimension by shape. Second
dimension gels are blotted and probed for regions of interest on chromosome III.
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Fig. 3.3 Shapes of replication intermediates
Non-replicating molecules are represented by a 1n spot located on the linear molecule
line. Replication that is initiated within a restriction site results in a series of bubble
shaped molecules representing initiation of bi-direction replication forks. A restriction
fragment lying between an origin and the terminus results in a series of Y shaped
molecules formed as a single replication fork moves through the restriction fragment. A
2n spike or X-spike represents the shape of recombination intermediates.
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initiated within a restriction site results in a series of bubble shaped molecules
representing initiation of bi-direction replication forks. A restriction fragment lying
between an origin and the terminus results in a series of Y shaped molecules formed as a
single replication fork moves through the restriction fragment. A 2n spike or X-spike
represents the shape of recombination intermediates.
The isolation of the cdc45-10 hypomorphic allele that conferred hypersensitivity
to the CPT mimetic, Top1T722A, supported a role for Cdc45 in protecting cells against
Top1-DNA damage. Because Cdc45 is essential for the initiation and elongation steps of
DNA replication, assessing origin firing and replication fork progression in cdc45-10
cells provided a unique opportunity to assess whether Cdc45G510R was defective in either
of these two fundamental steps. Indeed, using 2-D agarose gel analysis, we report that
Cdc45G510R caused a decrease and a delay in origin firing at ARS305 when cdc45-10
cells were shifted from 26˚C to 36˚C after release from α-factor arrest, with no apparent
alterations in replication fork progression. These results contrasted with the fragility of
the replication forks that was observed when cdc45-10 cells were shifted to the nonpermissive temperature prior to cell cycle arrest in G1-phase. Under these conditions, the
licensing of origins at 36˚C impaired the stability of the replication forks in S-phase.
Thus, Cdc45 function is required to ensure the timely firing of an early replication origin
and for the appropriate assembly of the replication machinery necessary to support
processive replication.
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3.2 EXPERIMENTAL PROCEDURES

3.2.1 Chemicals and yeast strains
The mating pheromone α-factor, purchased from US Biological, was stored at
-20˚C at 1mg/ml in methanol and used at a final 5μg/ml or 10μg/ml.
S. cerevisiae strains, cultured using standard conditions, were CSY6 (MATa,
ura3-52, his3Δ200, leu2Δ1, TRP1) and CLY16 (MATa, ura3-52, his3Δ200, leu2Δ1,
TRP1, TOP1, cdc45-10).

3.2.2 Analysis of cell cycle progression and 2-D gel electrophoresis of replication
intermediates
Asynchronous cultures of isogenic CDC45 and cdc45-10 cells, exponentially
growing at 26˚C, were diluted to an OD=0.3, then treated with 5 µg/ml α-factor to induce
cell cycle arrest in G1 phase. After 60 minutes the cells were shifted to 36˚C and an
additional 2.5 µg/ml α-factor was added, when greater than 95% of the cells exhibited a
schmoo phenotype indicative of α-factor arrest, the cells were released into S-phase by
filtration and resuspended in media pre-warmed to 36˚C. Alternatively, cells cultured at
36˚C, were arrested with 10 µg/ml a-factor for 60 minutes, and treated with an additional
5 µg/ml α -factor for 60 minutes. As above, cells were then released into S-phase in
media pre-warmed to 36˚C. At the times indicated, aliquots of the cells were collected by
centrifugation for western blot analysis (see below) or fixed with 100% ethanol and
processed for FACs analysis as described (49).
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Replication intermediates were also purified at 0 min, 10 min, 20 min, 40 min, 60
min, or 80 min following release of cells from α-factor into YPD as described (12). To
analyze ARS305, ARS305+6Kb, ARS305+18Kb or ARS305+29Kb replication
intermediates, purified DNA, restricted with Eco RV and Hind III, was resolved by 2-D
gel electrophoresis, transferred to nylon membranes, successively hybridized with 32Plabeled probes spanning ARS305, ARS305+6Kb, ARS305+18Kb or ARS305+29Kb and
visualized by PhosphorImage analysis. The probes were first PCR amplified from
genomic DNA (primer pairs available upon request), then α-32P-dATP labeled using a
Megaprime DNA Labeling kit from Amersham.

3.2.3 Western blot analysis
To assess Cdc45 and Cdc45G510R protein levels, NaOH/TCA extracts were
prepared from cells following release from α-factor as described (30). Cdc45 proteins
were detected by immunoblotting with a rabbit polyclonal Cdc45 antibody, followed by
an HRP-conjugated donkey anti-rabbit antibody and chemiluminescence (Pierce).
Immunostaining with tubulin antibodies served as loading controls.

3.3 RESULTS
Cdc45 is required for the initiation and elongation phases of DNA replication. We
previously reported that cdc45-10 mutant cells were hypersensitive to Top1-induced
DNA damage. These cells also exhibited a transient accumulation of Okazaki-sized DNA
fragments upon shift to the non-permissive temperature that suggested a defect in
processive DNA replication. While these findings suggested that alterations in
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Cdc45G510R function impaired the elongation of phase of DNA replication, they failed to
define the exact nature of this defect. To more precisely address this question, we used 2D agarose gel electrophoresis to investigate the efficiency of origin firing and replication
fork progression in cdc45-10 cells. To discriminate between defects in origin licensing in
G1-phase and processive DNA replication in S-phase, two experimental approaches were
taken.
As diagrammed in Fig. 3.4A, to address Cdc45 function in the elongation phase of
DNA replication, the cells were α-factor arrested in G1 phase of the cell cycle at the
permissive temperature of 26˚C, then released into S-phase at 36˚C. Under these
conditions, Cdc45G510R function in origin licensing would occur at the permissive
temperature, while DNA replication would be initiated at the non-permissive temperature
for Cdc45G510R. This contrasts with the experimental design diagrammed in Fig. 3.4B,
where the mutant and wild-type cells are shifted to 36˚C prior to α-factor arrest in G1phase. In this case, both origin licensing and replication occur at the non-permissive
temperature for Cdc45G510R. A comparison of these data would then allow us to define
the consequences of defects in Cdc45 function in both phases of the cell cycle.
At the permissive temperature of 26˚C, cdc45-10 cells exhibit a subtle slow growth
phenotype in the absence of exogenous DNA damage, which corresponds to a slight
delay in S-phase transit relative to isogenic wild-type cells cultured under the same
conditions (data not shown and the FACs profiles shown in Fig. 3.5). However, a survey
of several ARSs, including ARS305 and ARS607, failed to reveal any obvious defect in
origin firing (data not shown). However, this was not the case when cdc45-10 cells were
either shifted to 36˚C prior to S-phase transit, or cultured at 36˚C.
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Fig. 3.4 Experimental approaches for defining defects in origin licensing in G1phase and processive DNA replication in S-phase
(A) CDC45 and cdc45-10 cells were cultured at 26˚C, synchronized in late G1-phase
using α-factor and released into S-phase at 36˚C.
(B) CDC45 and cdc45-10 cells were cultured at 36˚C, synchronized in late G1-phase
using α-factor and released into S-phase at 36˚C.
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Fig. 3.5 CDC45 and cdc45-10 S-phase transit at 26˚C and 36˚C
At 26˚C, cdc45-10 cells exhibit a subtle slow growth phenotype in the absence of
exogenous DNA damage compared to CDC45, however, when cdc45-10 cells were
shifted to 36˚C, the slow S-phase transit was exacerbated.
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In the first case, i.e., following synchronization in late G1 at 26˚C, CDC45 and
cdc45-10 cells were shifted to 36˚C upon release into S-phase. Aliquots of cells were
collected at time 0, 10, 20 and 40 minutes following α-factor release. The replication
intermediates were extracted, digested with restriction enzymes specific for the regions of
interest on chromosome III and separated in an agarose gel on the basis of size. The
portion of the first dimension gel containing restriction fragments of 3.5 kilobases (Kb)
and larger were excised, rotated 90° and the replication intermediates were then separated
in the second dimension on the basis of shape. The DNA was then transferred to a nylon
membrane and successively hybridized with 32P-labeled probes specific for regions
spanning the left arm of chromosome III. The temporal pattern of ARS firing and
replication fork progression have been extensively characterized for chromosome III. In
wild-type cells, bi-directional DNA replication initiates at ARS305 early in S-phase.
Towards the left telomeric end of chromosome III, the remaining ARS elements,
ARS301-304, are cryptic and rarely fire. Thus, the timing of origin firing and the
progression of a lone replication fork that uniquely originates at ARS305 can be assessed
as the cells synchronously transit S-phase.
As shown in Fig. 3.6, following release into S-phase, CDC45 cells exhibited
prominent firing of ARS305 by 10 minutes, as evidenced by the appearance of a bubble
arc (arrow). In the FACs profiles of these cells, shown in Fig. 3.5, the cells accumulated a
2n DNA content by 40 minutes. This time frame also coincided with a second, less
intense round of DNA replication at ARS305 (Fig. 3.6), as the cells lose synchrony. These
data contrast with those obtained with cdc45-10 cells. As seen in Fig. 3.6, there was a
delay in the timing of ARS305 firing, as well as the extent of origin firing. A bubble arc
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Fig. 3.6 Alterations in Cdc45 function delays and decreases early origin firing but
does not affect replication fork progression
CDC45 and cdc45-10 cells were grown at 26˚C, synchronized in late G1 with α-factor
and released into S-phase a 36˚C. Replication intermediates were visualized using 2-D
gel electrophoresis, blotted and probed for ARS305, ARS305 + 6Kb and ARS305 + 18Kb.
cdc45-10 cells exhibit a delay and decrease in origin firing at ARS305 compared to
CDC45 cells. However, successive stripping and re-probing of the blots for regions 6Kb
and 18Kb away from ARS305 revealed that replication fork progression in cdc45-10 cells
was similar to that observed in CDC45 cells.
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was not detected until 20 minutes following release into S-phase and the signal was
consistently weaker than that observed with CDC45 cells. However, when the blots were
stripped of the ARS305 probe and re-probed for sequences 6Kb or 18Kb towards the left
telomeric end of the chromosome, the replication forks appeared to progress with the
same kinetics as those detected in CDC45 cells. This decrease in the timing and
efficiency of ARS305 firing coincided with a more pronounced decrease in S-phase
transit at 36˚C, as seen in the FACs profiles of Fig. 3.5. These data suggest that the
alterations in Cdc45G510R function in S-phase are restricted to the initiation of DNA
replication. However, this cdc45-10 phenotype could not be attributed to the selective
thermolability of the Cdc45G510R protein in S-phase upon shift to 36˚C. Indeed as seen in
Fig. 3.7, there was actually an increase in steady state levels of Cdc45G510R protein,
relative to wild-type Cdc45 protein, when cells were released into S-phase. Whether the
mutant protein exhibits alterations in chromatin association, and how this might impact
Cdc45 protein turnover has yet to be addressed. Nevertheless, the replication defects in
cdc45-10 cells are not a consequence of Cdc45G510R down regulation at the nonpermissive temperature.
We next considered the consequences of licensing ARS305 at the non-permissive
temperature, as diagrammed in Fig. 3.4B. In these experiments, CDC45 and cdc45-10
cells were cultured at 36°C, then synchronized in late G1 phase with α-factor and
released into S-phase at 36°C. Aliquots of cells were collected at 0, 10, 20, 40, 60, and 80
minutes after α-factor release and the replication intermediates were resolved as above.
As shown in Fig. 3.8, the temporal pattern of ARS305 firing in CDC45 cells was similar
to that observed in Fig. 3.6. A prominent bubble arc was detected by 10 minutes
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Fig. 3.7 cdc45-10 cells exhibit increased protein levels when origins are licensed at
26˚C and S-phase transit occurs at 36˚C
CDC45 and cdc45-10 cells were cultured at 26˚C, α-factor arrested and released into Sphase at 36˚C. Time points were collected; whole cell extracts were prepared and
visualized on western blots using a Cdc45 antibody and a tubulin antibody as a control.
cdc45-10 cells exhibited an increase in protein level compared to CDC45 cells.
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Fig 3.8 Licensing ARS305 at 36˚C alters replication fork stability in cdc45-10 cells
CDC45 and cdc45-10 cells were grown at 36˚C, synchronized in late G1 with α-factor
and released into S-phase a 36˚C. Replication intermediates were visualized using 2-D
gel electrophoresis, blotted and probed for ARS305. The intermediates isolated from
cdc45-10 cells were distributed along a linear diagonal with a DNA mass between 1n and
2n, implying initiation at ARS305 however, the intermediates failed to retain differences
in shape.
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following release from S-phase. In this case, a second round of replication was not
evident at later times due to a rapid loss of cell cycle synchrony (data not shown).
However, the results obtained with cdc45-10 cells were rather remarkable. In contrast to
the canonical distribution of replication intermediates along bubble and y-arcs, the
intermediates isolated from cdc45-10 cells cultured at 36˚C were distributed along a
linear diagonal with a DNA mass between 1n and 2n. Thus, although DNA replication
had initiated at ARS305 to yield a greater than 1n DNA content, the intermediates failed
to retain differences in shape. Replication fork stalling in vivo is typified by the
accumulation of a discreet spot along the Y-arc, while replication fork collapse in vivo
has been described as an increase in cone and X-spike signals, with a concomitant
decrease in bubble and Y-arcs (50). Rather, the pattern obtained in Fig. 3.8 is consistent
with replication fork collapse during the isolation of the intermediates. Indeed, this
interpretation is consistent with the extended tails emanating from the spots in 0, 10 and
20’ samples. Hybridization of this blot with the ARS305 + 6Kb probe revealed a similar,
albeit weaker, pattern of spots with very faint Y-arcs discernible in some samples (data
not shown). The fragility of these replication intermediates is also mirrored in the FACs
profiles, which demonstrate a board distribution of cells throughout S-phase (data not
shown), as opposed to the tight distributions that mark the S-phase transit of cdc45-10
cells in Fig. 3.5. However, as in cdc45-10 cells shifted to 36˚C, Cdc45G510R protein
levels in cells cultured at 36˚C were also elevated in S-phase, relative to wild-type Cdc45
protein levels (Fig. 3.9). Taken together, these data indicate that licensing of origins in
cdc45-10 cells at 36˚C altered the assembly of stable replication forks in the subsequent
S-phase, while the assembly of pre-RC complexes at 26˚C, followed by a shift to 36˚C as

82

Fig. 3.9 cdc45-10 cells exhibit elevated protein levels when origin licensing and Sphase transit occurs at 36˚C
CDC45 and cdc45-10 cells were cultured at 36˚C, α-factor arrested and released into Sphase at 36˚C. Time points were collected; whole cell extracts were prepared and
visualized on western blots using a Cdc45 antibody and a tubulin antibody as a control.
cdc45-10 cells exhibited an increase in protein level compared to CDC45 cells.
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cdc45-10 cells entered S-phase, only affected the temporal pattern and efficiency of
origin firing.

3.4 DISCUSSION
The cdc45-10 hypomorphic mutant was isolated in a yeast genetic screen for
conditional mutants exhibiting enhanced sensitivity to low levels of DNA damage
induced by Top1T722A, a mutant enzyme that acts as a CPT mimetic. Cdc45 is an
essential protein that functions in the formation of pre-RC complexes in late G1 phase, in
the recruitment of replication machinery components to initiate DNA replication and as a
processivity factor for the replicative Mcm2-7 helicase during the elongation phase of
DNA replication. Cdc45 lacks any identifiable enzymatic activity and any similarity to
known protein structural domains, other than a Cdc45-motif found in other members of
this conserved protein family. Thus, Cdc45 appears to function as a scaffold for the
assembly/recruitment of replication machineries.
Our previous characterization of cdc45-10 cells defined a single G510R
substitution in Cdc45 that conferred the synthetic lethal interactions of this mutant with
defects in Dpb11 function, the Rad9 DNA checkpoint and the Rad52 homologous
recombination pathway (data not shown) (22). Low resolution alkaline sucrose gradient
analyses indicated a transient accumulation of Okazaki-sized DNA fragments in cdc4510 cells upon shift to the non-permissive temperature, which was exacerbated in the
double cdc45-10,dpb11-10 mutant. These data suggested a common defect in polymerase
switching induced the synthetic lethality of the double mutant strain (22). However, our
recent studies of dosage suppressors in Chapter 2 demonstrate that the alterations in
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Cdc45G510R function, which enhance cell sensitivity to Top1 poisons, are distinct from
those that induce the synthetic lethality with dpb11-10.
Indeed, our analysis of origin firing and fork progression in synchronized cdc4510 and CDC45 cells cultured under various conditions demonstrate distinct alterations in
Cdc45G510R function in the assembly of the replication machinery and the temporal
regulation of origin firing. In G1-phase, when pre-RC assembly, i.e., licensing of a
replication origin, occurs at the non-permissive temperature for Cdc45G510R, the
replication forks assembled in the subsequent S-phase at 36˚C were quite fragile. This
phenotype was evident in the broad S-phase distribution of these cells (data not shown)
and the collapse of the replication intermediates during purification (Fig. 3.8). The
fragility of these intermediates precluded any assessment of the relative timing of
ARS305 firing or of the rate of replication fork progression. Nevertheless, the instability
of these complexes contrasted with the stable replication intermediates isolated from
cdc45-10 cells that were shifted to 36˚C following release from α-factor arrest. Thus, the
assembly of replication forks at 36˚C per se had no adverse effect on fork stability. This
interpretation of the data is further supported by the relatively tight distribution of cdc4510 cellular DNA content as cells transit S-phase at 36˚C in Fig. 3.5. Rather, these results
suggest that alterations in pre-RC assembly, due to specific defects in Cdc45G510R
function at 36˚C, impair the subsequent assembly of the replication machinery in Sphase. Cdc45 has been shown to physically interact with Mcm5; thus, it is tempting to
speculate that alterations in Cdc45G510R binding to Mcm5 could impact fork stability
through alterations in helicase activity. Unfortunately, a rigorous assessment of
Cdc45G510R interactions with other components of the pre-RC will have to await the
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development of antibodies capable of immunoprecipitating Cdc45G510R, as described in
Chapter 2. Nevertheless, such decreases in fork stability provide a mechanistic basis for
the synthetic lethal interactions with rad9∆ and rad52∆ mutants, as a functional DNA
damage checkpoint and homologous recombination, respectively, would enhance cell
survival by affecting the repair of collapsed forks. The assembly of fragile forks would
also enhance cell sensitivity to Top1 poisons, either as a consequence of direct collisions
between the replication machinery and the stabilized Top1-DNA complexes or the local
accumulation of positive supercoils in advance of the fork (8,51,52).
The formation of pre-RC at the permissive temperature, followed by S-phase
transit at the non-permissive temperature, revealed a role for Cdc45 in the timing and
efficiency of ARS305 firing. These findings suggest that the isolation of ARS1303 as a
weak dosage suppressor of cdc45-10 cell sensitivity to TopT722A (reported in Chapter 2),
may reflect an increase in plasmid DNA stability, rather than a direct effect on
Top1T722A-induced DNA damage. Whether dpb11-10 cells also exhibit similar defects in
origin firing has yet to be determined. Nevertheless, the ability of ARS1303 to dosage
suppress dpb11-10 and tah11-10 sensitivity to Top1T722A does imply a common
mechanism of suppression. However, the transient accumulation of Okazaki-sized DNA
fragments observed in both cdc45-10 and dpb11-10 cells (22) upon shift of asynchronous
cells to 36˚C, also suggests a common defect in fork stability. Indeed, as will be
discussed in Chapter 4, such mutation-induced alterations in fork stability would not only
enhance cdc45-10 and dpb11-10 cell sensitivity to Top1 poisons, such as CPT, but would
also exacerbate the adverse effects that rapamycin inhibition of TORC1 has on S-phase
progression.
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CHAPTER 4: RAPAMYCIN-INDUCED ALTERATIONS IN
S-PHASE TRANSIT

4.1 INTRODUCTION
As described in Chapter 2, a yeast genetic screen was used to isolate conditional
mutants that exhibit enhanced sensitivity to the self-poisoning Top1T722A mutant.
Several of these mutants, including hypomorphic alleles of CDC45 and DPB11, exhibit
alterations in DNA replication, which exacerbate the S-phase-dependent toxicity of the
Top1 poison, camptothecin. Surprisingly, many of these mutants were also hypersensitive
to the macrocyclic lactone antibiotic rapamycin (RAP) (53). RAP, in complex with
FKBP12, specifically targets TOR (target of rapamycin), a phosphatidylinositol 3-kinaserelated kinase family member that regulates cellular responses to a wide range of
environmental stresses such as nutrient starvation, growth factor deprivation and hypoxia.
These signals are transmitted by multi-protein complexes through a variety of
downstream pathways to regulate cap-dependent mRNA translation, transcriptional stress
responses, G1 to S-phase transition and cell survival (54-56). The dysregulation of AktTOR signaling has been associated with tumorigenesis, therefore, this pathway provides
potential targets for cancer chemotherapy (54,57). Currently RAP analogs are being
developed in clinical oncology trials.
The TOR kinase was initially identified from a genetic screen in S. cerevisiae for
mutants conferring resistance to RAP. In S. cerevisiae there are two closely related Tor1
and Tor2 kinases, while other eukaryotic genomes encode a single kinase, as exemplified
by mammalian mTOR (56). As in mammalian cells, TOR signaling in yeast regulates cell
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growth through the function of distinct multi-protein complexes as seen in Fig. 4.1
(56,58-60). In yeast, Tor1 or Tor2 is a component of a RAP-sensitive TOR1 complex
(TORC1) consisting of Kog1, Lst8 and Tco89. Mammalian TORC1 consists of mTOR,
raptor (a Kog1 analog) and mLst8. Under favorable environmental conditions, TORC1
regulates the accumulation of cell mass by controlling the translation initiation of a
limited subset of capped mRNAs, nutrient uptake and ribosome biogenesis. RAP
treatment or depriving cells of nutrients or essential growth factors induces a starvation
response characterized by decreased protein synthesis, macroautophagy and the induction
of stress response transcription factors (56).
A second complex, TORC2, is RAP “insensitive” and is involved in regulating
actin cytoskeletal organization during cell growth, endocytosis and calcineurin and
sphingolipid signaling. Although in some cells, TORC2 is also inhibited as a
consequence of long-term exposure to rapamycin (61). Yeast TORC2 consists of Tor2 in
complex with other conserved proteins such as Avo3 (rictor in mammalian cells)
(56,62,63).
The PI3K-related kinase family members ATM, ATR, DNA-PK, yeast Mec1 and
Tel1 have significant roles in repair and checkpoint responses to DNA damage (64).
Although a direct role for TOR signaling in S-phase has yet to be defined, several
observations suggest that TORC1 may function in response to DNA replication stress.
For example, when p53-/- mouse embryo fibroblasts or cancer cells mutant for p53 are
cultured under serum free conditions, RAP treatment induces apoptosis, which coincides
with entry into S-phase (65,66). Second, RAP inhibition of mTOR signaling has been
shown to enhance the cytotoxic activity of the DNA damaging agent cisplatin (67,68).
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Fig. 4.1 The TOR pathway
The TOR pathway regulates cellular response to environmental stress such as nutrient
starvation, growth factor deprivation and hypoxia. TOR1 or TOR2 can form a rapamycin
sensitive TORC1 complex involved in regulating cap-dependent translation,
transcriptional stress responses, cell cycle progression from G1 to S-phase and cell
survival. TOR2 can for a rapamycin insensitive TORC2 complex involved in actin
organization.
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Although, the underlying mechanisms affecting cell survival in S-phase remain unclear.
A third line of evidence derived from our studies of the hypomorphic alleles of CDC45
and DPB11 that are hypersensitive to Top1T722A-induced DNA damage and exhibit
alterations in DNA replication (22,30,34). These mutants are also hypersensitive to RAP
implying that TOR signaling plays a role in S-phase.
In this study we report that rapamycin-sensitive TORC1 signaling functions to
promote S-phase transit and maintain cell viability following Rad53 checkpoint
activation by DNA damage or replicative stress. In response to MMS-induced DNA
damage, TORC1 signaling was required to maintain the stability of stalled replication
forks independent of the Rad53 checkpoint. In contrast, in response to hydroxyurea (HU)
induced replication stress, TORC1 functioned to promote fork progression while cell
viability and replication fork stability were maintained by the Rad53 checkpoint. Thus,
TORC1 signaling appears to play distinct roles in S-phase in mediating cellular responses
to DNA lesion versus the prolonged stress imposed on the replication machinery by HU.

4.2 EXPERIMENTAL PROCEDURES

4.2.1 Chemicals and yeast strains
Hydroxyurea (HU) was purchased from U.S. Biological. RAP, obtained from the
NCI drug repository, was dissolved in dimethyl sulfoxide, and stock solutions of 1 mg/ml
were stored at -20˚C. The mating pheromone α-factor, from Diagnostic Chemicals Ltd,
was stored at -20˚C at 1 mg/ml in methanol and used at a final concentration of 5 μg/ml.
MMS was purchased from Sigma.
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S. cerevisiae strains, cultured under standard conditions, were CSY6 (MATa,
ura3-52, his3Δ200, leu2Δ1, TRP1) and CSY75 (MATa, ura3-52, his3Δ200, leu2Δ1,
sml1Δ::His3, rad53Δ::TRP1)

4.2.2 Cell cycle analysis and viability assays
MATa cells, a-factor arrested in G1 phase of the cell cycle, were washed by
filtration and released into medium alone, or medium supplemented with 200 ng/ml RAP,
0.05% MMS, 0.05% MMS plus 200 ng/ml RAP (MMS + RAP), 10 mg/ml HU, or 10
mg/ml HU plus 200 ng/ml RAP (HU + RAP). Isogenic strains prototrophic for
tryptophan synthesis were used to avoid the complications of RAP-induced down
regulation of the Tryptophan transporter. For cell viability assays, aliquots of the cells
were washed by centrifugation at the times indicated, to remove the drugs, serially tenfold diluted and plated to determine clonogenic survival at 30˚C. Aliquots of the cells
were also fixed with 70% ethanol and stored at 4˚C for subsequent FACs analysis.

4.2.3 2-D gel analysis of replication intermediates
Replication intermediates were purified at the indicated times following release of
the cells from α-factor into YPD or YPD plus RAP, MMS, MMS+RAP, HU or HU +
RAP as described (12). To analyze ARS305 replication intermediates, purified DNA,
restricted with Eco RV and Hind III, were resolved by 2-D gel electrophoresis,
transferred to nylon membranes, hybridized with a 32P-labeled probe spanning ARS305
and visualized by PhosphorImage analysis. To assess replication fork progression along
the left arm of chromosome III, the same blots were successively stripped and re-probed
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with radiolabeled DNA derived from genomic sequences 6Kb, 18Kb or 29Kb from
ARS305.

4.3 RESULTS

4.3.1 TOR signaling is a determinant of cell survival in response to DNA damage
RAP inhibition of TOR signaling induces yeast cell cycle arrest in early G1 phase,
which precedes the G1 block induced by the α-factor mating pheromone (69). Therefore,
as diagrammed in Fig. 4.2, we reasoned that TOR signaling in S-phase could be assessed
by first arresting cells in late G1 phase with the mating pheromone α-factor, then
releasing cells into media containing RAP, in the presence or absence of the DNAdamaging agent MMS or the ribonucleotide reductase inhibitor HU.
We, and others, have reported that when cells are released into media containing
RAP a subpopulation of α-factor arrested cells failed to transit S-phase (data not shown,
(53,69). However, our studies demonstrated that the kinetics of S-phase transit for those
cells that entered S-phase mirrored those of the untreated control cells with RAP-treated
cells accumulating in the next G1 phase. When cells were released into media containing
MMS, S-phase transit was decreased due to the activation of the Rad53 checkpoint. This
effect on S-phase transit has been well documented. However, our results demonstrate
that RAP treatment further delayed the slow S-phase transit induced by MMS (data not
shown). As shown in Fig. 4.3, under the same conditions, RAP treatment alone was
growth inhibitory not cytotoxic. In contrast, the cytotoxicity of MMS was enhanced by
co-treatment with RAP (compare MMS with MMS+RAP in Fig. 4.3). Thus, the further
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Fig. 4.2 Experimental design for assessing TOR signaling in S-phase
Asynchronous cultures were α-factor arrested in late G1-phase. The cultures were
released into S-phase into media as a control, MMS, rapamycin and MMS + rapamycin
to assess S-phase transit.
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Fig. 4.3 Rapamycin inhibition of TOR signaling decreases cell viability in response
to MMS treatment
Arrested cells were released into media with no drug, RAP, MMS or MMS + RAP. The
cells were serially diluted at the times indicated and the number of viable cells forming
colonies on YPD plates following incubation at 30˚C was plotted relative to time=0.
Error bars indicate standard deviations (n=3).
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delay in S-phase transit induced by MMS+RAP over that observed with MMS alone was
reflected in a proportional decrease in colony number over time.
We recently reported that TORC1 acts as a survival pathway in response to
genotoxic stress, in part, by maintaining the elevated expression of the ribonucleotide
reductase subunits Rnr1 and Rnr3 induced by DNA damage activation of the Rad53 Sphase checkpoint (53). Our findings supported a model whereby TORC1 acts as a
survival pathway in response to DNA damage by maintaining the deoxynucleoside
triphosphate pools necessary for error-prone translesion DNA polymerases. In fact as
diagrammed in Fig. 4.4, TOR-dependent cell survival in response to DNA damaging
agents coincides with increased mutation rates. Thus, one consequence of TORC1
signaling in the face of persistent DNA damage may be the acquisition of mutations that
confer drug resistance. However, the pronounced delay in S-phase transit induced by
MMS+RAP also led us to consider the effects that inhibiting TORC1 signaling might
have on the stability of the replication forks.

4.3.2 Replication fork stability is diminished by MMS + RAP
To assess origin firing and fork stability in cells treated with MMS +/- RAP,
replication intermediates resolved in 2-D gels, were probed with sequences
corresponding to the early replication origin ARS305 or flanking DNA (6Kb, 18Kb or
29Kb towards the left telomere of chromosome III), where ARS301-304 are normally
dormant. In these gels, a bubble arc reflects bidirectional origin firing and Y arcs result
from the asymmetric movement of replication forks through the restriction fragment
being probed. X-spikes accompany origin firing and decrease in intensity as forks
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Fig. 4.4 TORC1 acts as a survival pathway in response to DNA damage by
maintaining the dNTP pools
When the S-phase checkpoint is activated by DNA damage, ribonucleotide reductase
(RNR) is induced to maintain dNTP pools to for translesion of DNA synthesis and
survival. RAP inhibition of TORC1 inhibits the induction of RNR subunits thereby
decreasing levels of dNTP pools.
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migrate (12).
As shown in Fig. 4.5, after release into S-phase, firing of ARS305 was unaffected
by rapamycin, as evidenced by a robust bubble arc at 10 minutes. Untreated cells
continued to cycle: the bubble arc apparent after release from α-factor, was not detected
at 60 minutes and reappeared at 180 minutes as cells entered subsequent cell cycles. The
decrease in replication intermediates after 60 minutes of rapamycin treatment coincided
with the accumulation of cells in G1 phase. With MMS, the accumulation of a strong Y
arc and X-spike indicates slow fork progression at 30 minutes. The decrease in
intermediates at 60 minutes coincided with fork progression and the accumulation of cells
with a 2n DNA content. A slightly less intense pattern of replication intermediates was
obtained with MMS + RAP at 30 minutes. However, the decrease in replication
intermediates at 60 and 180 minutes, relative to MMS alone, did not correspond with
increased DNA content. A persistent cell cycle arrest in early S-phase due to Rad53
checkpoint activation would yield stable replication intermediates over the time course of
these experiments. Rather these data suggest a decrease in fork stability.
To directly assess these issues, we next assessed replication fork migration
towards the left telomere of chromosome III in isogenic strains wild-type for the Rad53
checkpoint or deleted for RAD53 (rad53∆). As shown in Fig. 4.6, similar blots of
replication intermediates obtained from cells released from α-factor into MMS alone or
MMS + RAP were successively re-probed with sequences 18Kb and 29Kb downstream.
Replication intermediates isolated from MMS-treated rad53Δ cells demonstrated
a more rapid progression of replication forks (relative to wild-type cells) with a strong Y
arc detectable at +29Kb by 60 minutes and little evidence of fork collapse. The dormant
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Fig. 4.5 MMS+RAP treatment diminishes replication fork stability
At the times indicated following α-factor release into YPD, MMS, RAP, or MMS+RAP,
replication intermediates were resolved in 2-D gels. The distribution of bubble arcs, Y
arcs and X-spikes, which indicate origin firing, passive DNA replication and slow fork
progression, respectively, was determined in southern blots with an ARS305 probe.
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Fig. 4.6 Decreased fork stability induced by MMS+RAP treatment is Rad53independent
Replication intermediates from wild-type and rad53Δ cells, released from α-factor into
MMS or MMS+RAP, were resolved in 2-D gels. The blots were successively hybridized
with probes derived from ARS305 and sequences 6Kb, 18Kb and 29Kb to the left of
ARS305 on chromosome III (the reverse orientation is diagrammed). Dormant ARS301,
302, 303 and 304 are in grey.
of ARS305. In MMS-treated wild-type cells, replication intermediates evident at ARS305
at 30 minutes, shifted to a strong Y arc at +18Kb by 60 minutes and had dissipated by
180 minutes, indicating continued fork progression. Only weak Y arcs were detected at
+29Kb. In contrast, the uniform decrease in Y arc signal along chromosome III seen in
MMS+RAP treated cells (Fig. 4.6) and concomitant delay in S-phase transit (data not
shown) indicated a decrease in fork stability.
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ARS301 at +29Kb also fired in MMS treated rad53Δ strains, as previously reported (12).
In contrast, the pattern of fork progression in rad53Δ cells treated with MMS+RAP
resembled that obtained with wild-type cells. Thus, the decreased fork stability induced
by MMS + RAP appeared to be Rad53-independent. We next asked if TORC1 only
maintains fork stability in response to DNA damage or also functions in response to
replicative stress, which does not involve translesion DNA synthesis. To address this
question, we also isolated DNA replication intermediates from wild-type and rad53Δ
cells treated with HU + or- RAP.

4.3.3 TORC signaling promotes fork progression in response to HU-induced
replication checkpoint activation
As diagrammed in Fig. 4.2, the same experimental approach was also used to
assess the consequences of inhibiting TORC1 signaling in the presence of HU. HU is a
potent inhibitor of ribonucleotide reductase. Although HU treatment activates the
Rad53checkpoint, this is a consequence of depleted dNTP pools inducing a slowing of
replication fork progression, which in turn triggers the checkpoint. Allosteric feedback
activation of ribonucleotide reductase holoenzyme activity ensures the production of
sufficient dNTP levels to maintain cell viability and yeast cells can withstand prolonged
exposure to HU without adverse affects on clonogenic survival. Since HU treatment does
not produce frank DNA lesions, we asked if RAP inhibition of TORC1 signaling would
adversely impact cell survival in the face of persistent replicative stress.
As shown in Fig. 4.7, checkpoint activation by HU slowed S-phase transit;
replication forks did progress, albeit at a reduced rate. And, as observed with MMS,
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Fig. 4.7 TORC1 signaling promotes replication fork progression and maintains the
viability of cells exposed to HU
Replication intermediates from wild-type and rad53Δ cells, treated with HU or HU +
RAP were resolved in 2-D gels and successively probed with sequences derived from
ARS305, 305+6Kb and 305+18Kb.

101

TORC1 inhibition further diminished the S-phase transit of cells treated with HU. Yet, in
stark contrast to MMS + RAP, the delay in cell cycle induced by HU + RAP resulted
from a more pronounced decrease in the fork progression, without detectable alterations
in fork stability. In HU treated wild-type cells, the ARS305 bubble arc accumulated at 60
minutes, independent of rapamycin. The slow progression of the Y arc induced by HU
(from +6Kb at 60 minutes to +18Kb at 180 minutes), was further delayed in the presence
of HU + RAP (a strong Y arc persists at +6Kb at 180 minutes). These results contrasted
with HU treatment of rad53Δ cells, which induced replication fork collapse, independent
of TORC1 signaling. Thus, unlike the situation with the DNA damage induced by MMS
treatment, in HU treated cells the inhibition of TORC1 signaling suppressed fork
progression, while Rad53 functioned to maintain fork stability.
However, when drug exposure was extended to 24 hours, cells treated with HU +
RAP exhibited a persistent arrest in early S-phase, accompanied by a ~30-fold drop in
cell viability (data not shown). In contrast, cells exposed to HU for 5-9 hours exhibited a
late S/G2 phase DNA content, and by 24 hours most cells were in G1 phase with little or
no loss of viability (data not shown). These findings suggest that TORC1 signaling is not
only required to promote replication fork progression, but also functions to maintain cell
viability in the presence of persistent replicative stress. Indeed, as shown in Fig. 4.8, HU
treatment dramatically slows the progression of the replication forks that initiate at
ARS305, such that a robust Y-arc is only detected at residues 18 Kb downstream from
ARS305 after 3 hours following α-factor release. A weaker, yet persistent Y-arc is
detected at 3-5 hours at +29 Kb. A weak bubble arc is also seen at 5 hours, indicative of a
small percentage of cells entering the next cell cycle. These data are consistent with the
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Fig. 4.8 TORC1 signaling is required for fork progression during persistent
replicative stress
Replication intermediates were isolated from cell released into media containing HU and
HU + RAP, visualized using 2-D gel electrophoresis, blotted and probe for ARS305,
ARS305 + 6Kb, ARS305 + 18Kb and ARS305 + 29Kb. Replication fork progression from
ARS305 is dramatically slowed when cell are released into HU, in contrast, cells released
into HU + RAP exhibit a persistent delay in fork progression.
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FACs profiles obtained under the same conditions (data not shown). In contrast, a
persistent delay in fork progression is obtained from HU+RAP treated cells. A robust
bubble arc persists from 1 through 5 hours, followed by appearance of a robust Y-arc at
more distal (+6Kb and +18 Kb) sites. However, consistent with the FACs profiles, a
similar pattern of robust Y-arcs are not detected at +29 Kb. Taken together, these data
suggest that TORC1 signaling is required for fork progression in the face of persistent
replicative stress, but not to maintain fork stability. Nevertheless, this prolonged
retardation of fork progression will ultimately impair cell viability.

4.4 DISCUSSION
Our findings revealed that rapamycin-sensitive TORC1 signaling functions to
promote S-phase transit and maintain cell viability following Rad53 checkpoint
activation by DNA damage or replicative stress. In response to MMS-induced DNA
damage, TORC1 appears to exhibit Rad53 checkpoint dependent and independent
functions. First, TORC1 signaling is required to sustain the DNA damage checkpointmediated induction of ribonucleotide subunits Rnr1 and Rnr3, thereby ensuring sufficient
ribonucleotide reductase activity to generate the high levels of dNTPs necessary for
translesion DNA synthesis to bypass MMS-induced DNA lesions. The regulation of
translesion synthesis of DNA adducts by this mechanism could also explain the increased
sensitivity of mammalian cells to cisplatin that is induced by rapamycin (68). Second,
TORC1 signaling was also required to maintain replication fork stability, independent of
the Rad53 checkpoint. Whether this phenotype results from a RAP-induced decrease in
the translation of replication fork components has yet to be assessed. Nevertheless, these
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findings support a model for the enhanced RAP sensitivity of cdc45-10 cells. The
fragility of forks assembled in cdc45-10 cells at the non-permissive temperature, which
suffices to slow S-phase transit and requires the S-phase checkpoint to maintain cell
viability, would be exacerbated by RAP-induced fork collapse. Similar considerations
would also hold for dpb11-10 cells. Indeed, the enhanced sensitivity of cdc45-10 and
dpb11-10 cells to RAP was only observed at the non-permissive temperature. Whether
the dosage suppressors defined in Chapter 2, or the SUMO site mutation in Cdc45 also
impacts the RAP sensitivity of cdc45-10 cells has yet to be determined.
The effects of RAP inhibition on TORC1 signaling in cells exposed to MMSinduced DNA damage contrasted with that of cells exposed to HU. When cells are
exposed to replicative stress, due to HU-induced depletion of dNTPs, fork stability was
dependent on Rad53, not TORC1 signaling. In the face of prolonged exposure to HU, the
forks are very stable; however, they fail to progress when TORC1 signaling is inhibited
by RAP and the cells will eventually die. These data suggest that in response to DNA
damage, RAP treatment impairs the activity of some factor or factors whose activity is
required to maintain fork stability. However, in HU treated cells, this activity is either not
required or is not affected by RAP and fork stability is maintained by Rad53.
In response to MMS or HU treatment, RAP does induce the down regulation of Rnr1 and
Rnr3 (data not shown) (53). In the case of MMS-induced DNA damage, the resultant
decrease in dNTP levels effectively suppresses translesion DNA synthesis such that the
mutagenic activity of MMS is repressed and cell viability is further compromised (53).
HU does not induce mutagenic DNA lesions, so the consequences of Rnr1/3 down
regulation are quite distinct. HU itself inhibits ribonucleotide reductase to partially
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deplete intracellular levels of dNTPs. However, the enzyme is also subject to allosteric
regulation such that a modest increase in activity provides sufficient dNTP levels to
maintain cell viability, although fork progression is severely hampered (as seen in Fig.
4.8). However, our findings suggest that the additional down regulation of Rnr1 and Rnr3
by RAP inhibition of TORC1 further reduces ribonucleotide reductase levels, thereby
effecting a much more severe depletion of dNTPs. In essence, the replication machinery
becomes starved for dNTPs, the building blocks of DNA, and the fork stalling is more
pronounced. In this case, Rad53 then plays a critical role in maintaining fork stability. In
the face of prolonged replication stress, the cells will eventually die. Thus, TORC1
signaling also functions as a survival factor in response to DNA damaging agents as well
as prolonged replication stress.
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CHAPTER 5: DISCUSSION

Eukaryotic DNA topoisomerase I (Top1) acts as a swivel to remove positive and
negative supercoils that accumulate during cellular processes such as DNA replication,
recombination and transcription through a mechanism of transient DNA strand cleavage
and religation (1,2). Top1 is a monomeric enzyme that forms a protein clamp around
duplex DNA. The active site (Tyr727 in yeast) acts as a nucleophile to cleave the
phosphodiester backbone of a single DNA strand, forming a covalent 3’ phospho-tyrosyl
linkage with the DNA. The 5’ end of the DNA rotates within this covalent Top1-DNA
complex about the nonscissile strand to relax the positive or negative supercoils. The
5’OH of the cleaved strand acts as a nucleophile in a second transesterification reaction to
resolve the Top-DNA intermediate and religate the DNA (1,2).
Top1 is the sole cellular target of the anticancer agent camptothecin (CPT). CPT
targets Top1 and intercalates between the ends of the cleaved strand, interacting with
both the DNA and the enzyme, to prevent the religation step of the catalytic cycle thereby
extending the life of the covalently linked Top1-DNA intermediate (70,71). These
stabilized drug-enzyme-DNA intermediates are formed in all stages of the cell cycle;
however the cytotoxic activity of CPT is S-phase dependent. There are two suggested
mechanisms to explain this S-phase toxicity. First, biochemical and genetic data provide
evidence that advancing replication forks collide with the stabilized CPT-Top1-DNA
complexes to induce irreversible DNA lesions that trigger checkpoint activation and cell
death (6). Second, recent single molecule studies using human Top1 and a CPT analog
topotecan, suggests a second mechanism where drug binding of Top1-DNA complexes
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induce the accumulation of positive supercoils in front of advancing replication forks that
could in turn block fork progression resulting in fork collapse and lethal DNA lesions that
induce cell death (8). Despite extensive study, remarkably little is known of the
molecular interactions involved in converting the drug-enzyme-DNA complexes into
DNA lesions that trigger checkpoint activation or the downstream pathways required for
the resolution and repair of these lesions.
The genetically tractable budding yeast, S. cerevisiae, has been extensively used
to study cellular processes such as DNA replication and the mechanism of cancer
therapeutics (29) as most basic cellular processes, cell cycle machinery and mechanism
of cell sensitivity and resistance to CPT are highly conserved from yeast to human.
Using S. cerevisiae as a model system, a genetic screen was designed to isolate
conditional temperature sensitive mutants that exhibit enhanced sensitivity to the CPT
mimetic, Top1T722A. This self-poisoning enzyme exhibits a decrease in the rate of DNA
religation. Yeast cells can tolerate low-level expression of this enzyme making it a
valuable tool for identifying gene products and pathways that mediate cellular responses
to CPT, while avoiding the complication of drug uptake and efflux. From this genetic
screen, ten recessive tah mutants were identified. These mutants were unable to survive
the damage induced by Top1T722A at 36˚C due to the loss or decrease of TAH gene
product function. The tah mutants function in a variety of cellular pathways. One TAH
gene identified, UBC9, encodes the sole E2 conjugating enzyme in the SUMOylation
pathway. Three of the TAH genes are essential for DNA replication. CDC45 encodes a
DNA replication initiation factor that is essential for the initiation and elongation steps of
DNA replication. DPB11 encodes a subunit of the DNA polymerase II epsilon (ε)
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complex that is essential for the loading of DNA polymerases to initiate DNA synthesis
and is required for the S-phase checkpoint. TAH11 encodes a DNA replication licensing
factor required for pre-replicative complex formation (5).
The tah mutant cdc45-10 has a single amino acid substitution (G510R). These cells
are hypersensitive to Top1T722A expression at 36˚C and transiently accumulate in early
S-phase when shifted to 36˚C due to a defect in Okazaki fragment maturation. cdc45-10
cells also exhibit a slow growth phenotype when RAD9 is deleted suggesting that the
damage accumulating in these cells is sensed by the Rad9 DNA damage checkpoint.
cdc45-10 exhibits a synthetic lethal interaction with another tah mutant, dpb11-10, which
coincides with a persistent accumulation of Okazaki sized DNA fragments. Despite
extensive study, the function Cdc45 during the initiation and elongation steps of DNA
replication has yet to be defined. Our results imply that Cdc45 functions normally to
protect cells against Top1-DNA damage. Therefore, further characterization of the
replication defects in cdc45-10 cells would provide insights into the molecular
interactions required to protect cells against Top-induced DNA damage.

5.1 CDC45 HAS TWO DISTINCT FUNCTIONS
Isolation of cdc45-10 as a hypomorphic allele exhibiting enhanced sensitivity to
Top1T722A suggests that Cdc45 normally functions to protect cells against Top1-induced
DNA damage. Increased gene dosage of this mutant allele restored cellular resistance to
low-level expression of Top1T722A at 36˚C, however, failed to suppress the synthetic
lethality of cdc45-10,dpb11-10 cells. These results suggested that the essential function
of Cdc45 needed to protect cells from Top1 poisons is distinct from the functional
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interactions that are essential to maintain cell viability and Okazaki fragment maturation.
The alterations observed in cdc45-10 could not be attributed to thermolability of the
protein as steady state protein levels of Cdc45G510R in asynchronus cultured mirrored
those of Cdc45. In addition, the results obtained in the cdc45-10 high copy suppressor
screen also suggested two distinct functions of Cdc45. The dosage suppressors isolated
complemented cdc45-10 cell sensitivity to Top1T722A but failed to restore cell viability to
the cdc45-10,dpb11-10 double mutant strain at 36˚C. These two distinct functions of
Cdc45 is further supported by the results obtained from our attempts to epitope tag
Cdc45. Incorporating an HA tag at the C-terminus of Cdc45 resulted in a protein that
could maintain cell viability in plasmid shuffle assays, however, failed to complement the
synthetic lethality of the cdc45-10,dpb11-10 double mutant strain. In contrast,
incorporating a C-terminal HA tag on cdc45-10 resulted in a protein that could not
maintain cell viability suggesting that the C-terminus of Cdc45 functionally interacts with
the residues spanning Gly510 such that modifying the C-terminus results in a lethal
protein. With the exception of a bipartite nuclear localization signal, the amino acid
sequence of Cdc45 does not predict similarities with any known domains. Therefore,
having the X-ray structure of Cdc45 would provide a means of visualizing the functional
interaction between the C-terminus of the protein and region spanning the Gly510.

5.2 DOSAGE SUPPRESSORS OF cdc45-10 SUGGEST DISTINCT DEFECTS
Increased gene dosage of cdc45-10 suppressed the hypersensitivity of the cells to
Top1T722A at 36˚C, but not the synthetic lethality of cdc45-10,dpb11-10 cells. To define
pathways specific for cellular resistance to Top1 poisons, we used a yeast genetic screen
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to identify extragenic dosage suppressors of cdc45-10 sensitivity to Top1T722A. The
characterization of the two dosage suppressors isolated suggested distinct defects in
Cdc45G510R. The first suppressor, ARS1303, is an origin of replication located on
chromosome XIII. Isolation of this suppressor suggests a defect in origin licensing or
firing in cdc45-10 cells. This dosage suppressor also complemented the tah phenotype of
dpb11-10 and tah11-10, which are also essential during DNA replication. To date, very
little information is available for ARS1303, therefore, determining if this ARS sequence
normally fires during S-phase and the temporal pattern of this firing would provide
valuable information to further characterize this dosage suppressor. Furthermore,
determining if other ARS sequences such as ARS305 or ARS309 could dosage suppress
cdc45-10, dpb11-10 or tah11-10 would determine if ARS1303 is a unique ARS sequence
with distinct dosage suppressor function or if simply increasing the number of origins on
a plasmid increases the likelihood of at least one origin firing per cell and therefore
contributes to the stability of the plasmid in the cell.
The second dosage suppressor, SIZ1, encodes a gene product that functions in the
SUMOylation pathway as an E3 ligase. This suppressor restored cell viability to cdc4510 and ubc9-10 in the presence of Top1T722A at 36˚C suggesting that SUMO
modification of target proteins is required to protect cells from Top1 poisons. The amino
acid sequence of Cdc45 revealed one consensus SUMO site, however, mutating the
consensus SUMO site in Cdc45 did not alter cell sensitivity to CPT or HU at 36˚C, but
mutating this same site in cdc45-10 enhanced the temperature sensitivity and CPT and
HU sensitivity at 36˚C. Moreover, Cdc45SUMO did not restore cdc45-10,dpb11-10 cell
viability. Altogether, these results suggest that mutating this site has no effect on the drug
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sensitivity of Cdc45, but does alter the essential function of Cdc45 needed for the
interaction with Dpb11. Therefore, determining if Cdc45 is a target for SUMO
modification and if this modification is altered in Cdc45SUMO or cdc45-10 may provide
insight into the defects that alter the essential function of these proteins. Furthermore,
since Cdc45 is a scaffolding protein that interacts with many different components of the
replication machinery, immunoprecipitation assays can be utilized to determine defects in
Cdc45SUMO and cdc45-10 binding to known interacting proteins such as Dpb11 or Mcm5.

5.3 CDC45 FUNCTION IS REQUIRED FOR TIMELY ORIGIN FIRING AND
APPROPRIATE ASSEMBLY OF REPLICATION MACHINERY
Cdc45 is essential for initiation and elongation during DNA replication, therefore
assessing origin firing and replication fork progression in cdc45-10 cells identified the
alterations evident in these cells. We utilized two distinct experimental approaches to
address defects occurring in the licensing step (G1) or the initiation and elongation steps
(S-phase). The first approach was to synchronize cultures in late G1 at the permissive
temperature release the cells into S-phase at the non-permissive temperature. This would
permit licensing to occur at the permissive temperature, while replication would occur at
the non-permissive temperature. Under these conditions cdc45-10 cells exhibited a
decrease and delay in origin firing at ARS305, however, replication forks progressed with
kinetics similar to wild-type suggesting that Cdc45G510R cells were defective in the
initiation step only. This cdc45-10 phenotype was not the result of a thermolabile
Cdc45G510R protein as we observed an increase in Cdc45G510R steady state protein levels
compared to wild-type when cells were released into S-phase at 36˚C. These results
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imply that the replication defects in cdc45-10 cells is not the consequence of Cdc45G510R
down regulation when cells are shifted to 36˚C.
The second approach was to culture cdc45-10 at 36˚C prior to G1 arrest where
licensing and replication would be carried out at the non-permissive temperature. Under
these conditions replication forks appeared to be distributed along a linear diagonal with
a DNA mass between 1n and 2n implying that DNA replication had initiated at ARS305,
however, the intermediates isolated were fragile and collapsed upon purification. As in
the previous experiment, the protein levels of Cdc45G510R in the cells cultured at 36˚C
were also elevated in S-phase compared to Cdc45. Altogether these results indicate that
origin licensing in cdc45-10 cells at 36˚C altered the assembly of stable replication forks
in subsequent S-phase such that they collapse upon purification, while the assembly of
pre-RC complexes at 26˚C, followed by S-phase progression at 36˚C, only affected the
temporal pattern and efficiency of origin firing in cdc45-10 cells.
Cdc45 has been shown to be a scaffolding protein that interacts with components
of the replication machinery including Dpb11, Mcm5 and the GINS complex. Therefore,
determining if Cdc45G510R is defective in binding to any of the known interacting
proteins may provide an explanation for the alterations observed in replication fork
stability. The development of an antibody capable of immunoprecipitating Cdc45G510R
will provide the answers to these questions.

5.4 RAPAMYCIN-INDUCED ALERATIONS IN S-PHASE TRANSIT
A yeast genetic screen was designed to isolate conditional mutants exhibiting
enhanced sensitivity to the self-poisoning Top1T722A (5). Surprisingly, several of these
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mutants were also hypersensitive to the macrocyclic lactone antibiotic rapamycin (RAP),
including CDC45 and DPB11 (53). RAP, in complex with FKBP12, specifically targets
TOR (target of rapamycin), a phosphatidylinositol 3-kinase-related kinase family member
that regulates cellular responses to a wide range of environmental stresses such as
nutrient starvation, growth factor deprivation and hypoxia. These signals are transmitted
by multi-protein complexes through a variety of downstream pathways to regulate capdependent mRNA translation, transcriptional stress responses, G1 to S-phase transition
and cell survival (55,57,58). Several reports including our report that CDC45 and DPB11
are sensitive to RAP, implies a role for TOR signaling in S-phase, as these hypomorphic
alleles are essential for the initiation and elongation steps during DNA replication
(65,66).
In yeast cells, RAP inhibition of TOR signaling induces cell cycle arrest in early
G1. This arrest precedes the G1 block induced by α-factor (69) providing a means for
assessing TOR signaling in S-phase. When cells were released into media containing
RAP, a subpopulation of α-factor arrested cells did not transit S-phase, however, the
kinetics of S-phase transit for those cells that did enter S-phase were similar those of the
untreated control cells with RAP-treated cells accumulating in the next G1 phase. When
cells were released into media containing MMS, S-phase transit was slowed due to the
activation of the Rad53 checkpoint. In contrast, when cells were treated with MMS +
RAP a further delay in the slow S-phase transit was observed. RAP treatment alone is
growth inhibitory not cytotoxic. However, MMS treatment is cytotoxic and this
cytotoxicity is enhanced when cells are co-treated with RAP + MMS which is evident by
a proportional decrease in colony number that we observed over time.
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We previously reported that TORC1 signaling is required to maintain the elevated
expression of the ribonucleotide reductase subunits, Rnr1 and Rnr3, to maintain dNTP
pools for tranlesion synthesis and survival in response to genotoxic stress (53). The
results observed in the MMS+RAP treated cells suggested a role for TORC signaling in
stabilizing replication forks in cells exposed to DNA damage. Using 2-D gel analysis we
assessed origin firing and fork stability in cells treated with MMS +/- RAP. RAP
treatment did not affect origin firing at ARS305 and cells moved through S-phase with a
subpopulation accumulating in the subsequent G1 phase. MMS treated cells exhibited
slow fork progression, however, these cells did accumulate a 2n DNA content. A slightly
less intense pattern of replication intermediates was obtained with MMS + RAP
treatment suggesting a decrease in replication fork stability. To determine if these results
were dependent on the Rad53 checkpoint pathway, the same experiments were conducted
in cells lacking Rad53 (rad53Δ). Replication intermediates isolated from MMS-treated
rad53Δ cells demonstrated a more rapid progression of replication forks compared to
wild-type with little evidence of fork collapse. The cryptic origin ARS301 fired in these
cells as previously reported (12). When rad53Δ were treated with MMS + RAP the
pattern of fork progression observed was similar to that of wild-type suggesting the
decrease in fork stability induced by MMS + RAP appeared to be Rad53-independent.
To determine if TORC1 also functions in response to replicative stress, replication
intermediates were isolated from wild-type and rad53Δ cells treated with HU +/- RAP.
HU treatment results in inhibition of ribonucleotide reductase causing a depletion of
dNTP pools and activating the Rad53 checkpoint to inducing a decrease in replication
fork progression. Sufficient dNTP levels are produced to maintain cell viability due to
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allosteric feedback activation of ribonucleotide reductase holoenzyme activity. This
allows cells to withstand prolonged exposure to HU without adverse affects on cell
viability. HU treated cells exhibited a slowed S-phase transit due to checkpoint
activation, however, the replication forks did progress. Similar to MMS treatment, cells
treated with HU + RAP exhibited a further delay in S-phase transit. In contrast to MMS +
RAP, the HU + RAP treated cells exhibited a more pronounced decrease in the fork
progression, without affecting fork stability. HU treatment of rad53Δ cells resulted in
replication fork collapse and this was independent of TORC1 signaling. Therefore in HU
treated cells the inhibition of TORC1 signaling suppressed fork progression, while Rad53
functioned to maintain fork stability. When cells were exposed to replicative stress for an
extended period of time (HU at 24 hours), no decrease in cell viability was observed. In
contrast, when cells were treated with HU + RAP for 24 hours an arrest in early S-phase
with a decrease in cell viability was observed. Together these findings suggest that
TORC1 signaling is required to promote replication fork progression and also functions
to maintain cell viability in the presence of persistent replicative stress.
In this study, we suggest two independent functions of TORC1 signaling in Sphase. First, TORC1 signaling functions to promote S-phase transit and maintain cell
viability following Rad53 checkpoint activation by DNA damage or replicative stress.
Second, TORC1 signaling is also required to maintain replication fork stability,
independent of the Rad53 checkpoint. One consequence of RAP inhibition of TORC1
signaling is a decrease in protein translation, therefore analyzing mRNA and protein
levels of the replication fork components in cells treated with RAP will provide evidence
as to the exact defects observed as a result of RAP treatment.
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Our studies suggest a model for the enhanced RAP sensitivity of cdc45-10 and
dpb11-10 cells. This enhanced sensitivity to RAP occurred at the non-permissive
temperature only, which corresponds to the observation of fragile replication forks in
cdc45-10 cells at 36˚C. Therefore, determining if treatment of these cells with RAP
exacerbates this phenotype by inducing fork collapse would determine if our model is
correct. In addition, determining if the suppressors isolated in the cdc45-10 high copy
suppressor screen, or the Cdc45SUMO or Cdc45SUMO, G510R mutants alter cdc45-10
sensitivity to RAP will further characterize the defects observed in these cells.
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